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To compare patient characteristics and healthcare costs between newly-treated 
DPN patients receiving mono-pharmacotherapy and those receiving combination 
pharmacotherapy. 
A patient cohort was identified diagnosed with DPN during 2006-2013 in 
Inovalon’s MORE2® registry, a healthcare data warehouse with national 
medical/pharmacy claims, continuously enrolled for at least 18 months. Patients were 
included if they were ≥18 years at the time of their first DPN prescription for a tricyclic 
antidepressant (TCA), opioid, duloxetine, gabapentin, pregabalin, or any route lidocaine. 
They were classified as having mono- or combination pharmacotherapy (time between 
the first and second medicine was within 30 days). If there was a 60-day prescription fill 
gap, the prescription was classified as discontinued. Switch or add-on groups were 
categorized based on continuation of the index medicine. A simple proportional hazards 
model was conducted for comparing time to discontinue, switch, or add on. Multiple 
logistic regression was used for identifying predictors of combination pharmacotherapy. 
 There were 7,145 patients on mono-pharmacotherapy and 421 patients on 
combination pharmacotherapy. The top three index medicines were gabapentin (55.7%),  
opioids (13.1%), and pregabalin (12.9%) in the mono-pharmacotherapy group, and 
opioids+gabapentin (27.1%), TCAs+gabapentin (17.6%), and duloxetine+gabapentin 





more likely to discontinue their medications than patients on mono-pharmacotherapy. 
There was no statistically significant difference in time to switch (p=0.254) and add on 
(p=0.069) between mono- and combination pharmacotherapy. Patients who were female, 
with >7 co-morbidities, and who had depression or arthritis were more likely to start with 
combination pharmacotherapy. Patients who were older than 65 and those with 
hypertension were less likely to start with combination pharmacotherapy. The total post- 
minus pre-index cost had no statistically significant difference between mono- and 
combination pharmacotherapy (p=0.66).  
 Newly-treated DPN patients should add on another medication sooner than 30 
days when considering combination pharmacotherapy. Because all first-line medications 
have similar efficacy, the cost should be considered in the treatment decision. For this 
reason, gabapentin and TCAs are recommended. If considering the pre-index costs, 
taking combination pharmacotherapy will not cost more money; the policy maker can 
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1.1 Epidemiology and Burden of Diabetic Painful Neuropathy 
 
1.1.1 Definitions of DPN 
 
The United States is experiencing a diabetes epidemic. In 2012 approximately 
29.1 million Americans, or 9.3% of the population, had diabetes mellitus (DM) - a 
disorder of carbohydrate metabolism.
1
 Approximately 60 to 70% of DM patients develop 
peripheral neuropathy. Peripheral neuropathy is the most common complication of DM, 
followed by retinopathy and nephropathy.
2
 Diabetic neuropathy patients can be grouped 
into focal and diffuse groups. The diffuse group includes patients with chronic and 
progressive pain, and is more common than focal neuropathies.
3 
Diffuse neuropathy 
patients can have either distal symmetrical sensorimotor polyneuropathy (DSPN) or 
diabetic autonomic neuropathy.  
Some DSPN patients lose some or all sensation without pain, feeling tingling or 
numbness.
4
 About half of the patients who lose sensation in affected areas will develop 
diabetic painful neuropathy (DPN) as well.
4
 For those who experience pain, there are 
different categories of neuropathic pain depending on the symptoms and signs. The first 
is spontaneous pain, which presents in the absence of any stimulation; it is usually 





evoked pain, which presents in response to either a normally nonpainful stimulus 
(allodynia), or as having an increased pain response to a normally painful stimulus 
(hyperalgesia). The third and fourth are abnormal sensations in neuropathic-pain patients, 
paresthesia and dysesthesia, which are described as itching, numbness, tingling, and pins-
and-needles sensations.
5
 A cross-sectional cohort survey (painDETECT) conducted in 
Germany presented the following clinically relevant symptoms of DPN: prickling (35%), 
burning (33%), numbness (30%), pain (29%), pressure (22%), and allodynia (18%).
6
 Due 
to the variety of clinical symptoms, clinicians define DPN in different ways, resulting in 
DPN not having universally accepted criteria for diagnosis. Therefore, there is no 
standard rate of prevalence among diabetic patients in clinical practice.
7
 One 2011 
community-based study (n=15,962) assessed DPN through neuropathy symptom scores 
(NSS) and neuropathy disability scores (NDS) and reported the prevalence of the disease 
as 21% in the UK.
8
 Another UK multicenter study (n=6487) assessed DPN through NSS 
and NDS and reported the prevalence of DPN as 28.5% in diabetic patients.
9
 Overall, the 
prevalence of DPN is around 20-30% in diabetes patients.   
The pathogenesis of DPN remains unknown. Potential mechanisms include the 
following: increased blood glucose instability,
10
 increased peripheral nerve epineurial 
blood flow,
11
 altered foot skin microcirculation,
12
 reduced intraepidermal nerve fiber 
density,
13
 increased thalamic vascularty,
14
 and autonomic dysfunction.
15
 There are 
multiple mechanisms involved in the pathogenesis of DPN, which seem to be mutually 
interconnected and act in a synergistic way. That is to say, DPN is not the result of a 
single etiology or a specific lesion, but is produced by heterogeneous conditions.  





activity, diabetic nephropathy, dyslipidemia, peripheral arterial disease, and the severity 
of sensorimotor deficits.
3
 The National Diabetic Information Clearinghouse also stated 




1.1.2 Co-morbidities of DPN 
 
Cardiomyopathy, nephropathy, and retinopathy are the most common co-
morbidities of DM in DPN patients. Foot ulcers and infections also occur and may lead to 
nontraumatic lower limb amputations.
5
 A study from Kaiser Permanente Colorado 
assessed DPN co-morbidities between 1998 and 2003; Ritzwoller found that there was an 
almost ten-fold higher rate of limb amputations and more than twice the incidence of 
limb infection for pain-experiencing DPN patients compared to nonpainful DM 
patients.
17
  Mental disorders are also a common co-morbidity of diabetes mellitus in DPN 
patients. A systematic review conducted by Egede et al. concluded that individuals with 
Type 2 DM (T2DM) were 60% more likely to be diagnosed with depression than those 
without T2DM.
18
 Multiple co-morbidities are the common clinical characteristics in DPN 
patients. Sadosky et al. described the average number of co-morbidities as 3.1± 2.18 in 
DPN patients.
19
 A 6-month, multicenter study conducted in Germany found that 89.5% of 
DPN patients reported co-morbidities, including hypertension (70.5%), hyperlipidemia 
(39.2%), depression (24.8%), retinopathy (9.2%), and nephropathy (9.1%) .
20
 Similar 












1.1.3 Quality of Life of DPN 
 
DPN affects patients’ health-related quality of life (HRQoL) and functioning 
causing clinically important disability, distress, anxiety, and sleep disorders.
22
 In a UK 
HRQoL study, the neuropathic pain was confirmed through a Self-complete Leeds 
Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire. The 
bodily pain of the cohort was assessed through a Medical Outcomes Study 36-item 
short form (SF-36),
23
 and the scores of neuropathic pain (40.99) were statistically 
lower than for chronic pain (55.77) and no chronic pain (84.78) (p<0.001). Even after 
adjusting for age and pain severity, the HRQoL in neuropathic pain patients (48.89) 
was still poorer than in chronic pain patients (54.44), on a scale of zero to one hundred 
with zero meaning no pain and one hundred meaning pain as bad as the patient could 
imagine.
24
 The same study showed neuropathic pain was associated with every 
dimension of general health: physical functioning, physical role, bodily pain, general 
heath, vitality, social functioning, emotional role, and mental health. Overall, the 
HRQoL in DPN patients is poor, and the pain affects most aspects of their daily life.  
 
1.1.4 Costs of DPN 
The burden of DPN is expected to rise as diabetes becomes more prevalent in an 
aging and overweight population. A recent observational UK study reported that the 
annual incidence of DPN increased over 2006 to 2010 from 2.7 to 3.8 per 100,000.
25
 
While this differential incidence in DPN may appear unimportant, the cost of the disease 
is life-long. Total medical costs assessed for DPN at Kaiser Permanente Colorado were 





($6,651), because patients with DPN encountered a higher proportion of hospital costs 
relative to any other category of utilization costs. Total annual costs were increased with 
female gender, older age, and co-morbidities.
17
  One 2006 IMS Health & Medstat study 
in the US reported that the average annual costs of patients with DPN were significantly 
higher than those with the matched underlying disease (Medstat: $40,705 vs. $30,349; 
IMS Health: $22,754 vs. $16,467).
26
 Dworkin et al. reported that the much higher health- 
care costs in the Medstat group compared to the IMS health group were due to the 
patients in the Medstat group being generally older and having more co-morbidities. The 




In addition to the high costs of DPN care, these patients also have high levels of 
healthcare resource utilization including physician visits, hospital stays, and medicine 
use.
22
  Gore et al. showed that one-third of DPN patients had a hospitalization, and 39% 
of them utilized ER services.
21
 Furthermore, Ritzwoller found that pain-experiencing 




Nevertheless, DPN also leads to higher indirect costs resulting from work loss —
mainly absenteeism, presenteeism, or reduced productivity in the workplace.
28
 Stewart et 
al. reported that symptomatic DPN patients lost 1.4 more hours of work per week than 
the patients without symptomatic DPN (p<0.05).
28
 Tolle et al. found approximately one-
third of the DPN patients (35%) had lower employment status: reduced work time (15%), 
disability (12%), unemployment or early retirement (8%).
29 Overall, the annual indirect 





(WHI) during August 2001 to February 2004, which was calculated by multiplying lost 
hours by self-reported hourly earnings.
28
 The WHI is a validated computer –assisted 




1.2 Pharmacotherapy for Diabetic Painful Neuropathy 
 
The Diabetes Control and Complication trial (DCCT) showed that in Type I 
diabetes (T1DM) patients intensive insulin treatment reduced the risk of developing DPN 
by 60% to 69%, which persisted for another 13 to 14 years,
31
 yet the impact of tight 
glycemic control was smaller in T2DM patients.
32
 The Action to Control Cardiovascular 
Risk and Diabetes trial randomized 10,251 T2DM patients through their HbA1c level. 
The intensive glycemic control group (HbA1c < 6%) reduced the annual risk of 
developing DSPN by 0.7%, and they reached a modest 5% reduction after 3.7 years, but 
the difference was not statistically significant.
33
 Overall, the meta-analysis in a Cochrane 
review showed enhanced glucose control (more frequent subcutaneous insulin 
administration, continuous insulin infusion, oral antidiabetic agents, lifestyle 
modifications such as diet and exercise, or pancreas transplant) reduced the risk of 
developing clinical neuropathy by 1.84% (95% confidence interval (CI): -1.11 to -2.56) 




Guidelines for DPN management were published in 2010 and 2011 by the 
International Association for the Study of Pain (IASP) Neuropathic Pain Special Interest 
Group (NeuPSIG),
35
 the European Federation of Neurological Societies (EFNS),
36
 the 
American Academy of Neurology (AAN),
37







 and the Toronto Expert Panel on Diabetic Neuropathy 
(TEPDN).
39
 Each guideline has its own evidence grading system. In general, NICE, 
NeuPSIG, and TEPDN add authors’ clinical experience to their pharmacotherapy 
recommendations, but AAN and EFNS guidelines are based solely on evidence-based 
medicine.
40, 41
 The AAN guideline had higher level A evidence than the EFNS guideline: 
the AAN guideline required at least two class 1 studies, whereas the EFNS guideline 
required at least one class 1 or two class 2 studies. The various guidelines were generated 
through different organizations and were written for different audiences. The TEPDN 
guideline is based on the opinioned experts in the Diabetic Neuropathy Study Group 
ascertained at the 2009 International Diabetic Neuropathy Symposium held in Toronto. 
The NICE guideline is funded by the UK NHS (National Health Service) and is written 
for nonspecialist providers; therefore, the cost-effectiveness for NHS is considered in 
NICE. The NeuPSIG guideline addresses neuropathic pain syndromes and is not 
specifically for DPN.  
All guidelines indicate that clinicians have difficulty managing DPN in clinical 
practice due to the presence of co-morbidities, contraindications, the possible drug-drug 
interactions (DDIs),
42
 and the different responses to medication.
43
 The guidelines suggest 
that patients should be offered the available therapies in a stepwise fashion.
35, 38
 If 
patients do not respond adequately to first-line treatment, or complain of adverse events, 
they may need to modify their treatment. Most guidelines recommend a TCA including 
nortriptyline, desipramine, or tertiary amine TCA (25-150 mg/day) or duloxetine (60-120 
mg/day) as first-line agents, but the AAN choose only pregabalin (150-600 mg/day) as a 







 but not by NICE, which prefers amitriptyline as first-line treatment 
instead (Table 1.1-1.2). The recommended next steps of the guidelines are as follows: 
change to another first-line agent; change to a second-line agent; or add a different first- 
or second-line agent.
35
 NICE suggests that if symptoms do not improve at the maximum 
tolerated dose (MTD), switch to pregabalin instead of adding it.
38
 TEPDN states that if 
the pain is still not well-controlled, add opioids such as tramadol and oxycodone as a 
combination treatment.
44
 EFNS recommends that if patients show partial response to 
drugs administered alone, use gabapentin combined with nortriptyline as the next step. 
36
  
In conclusion, TEDPN, NeuPSIG, EFNS, NICE, and AAN suggest 
gabapentinoids (e.g., pregabalin, gabapentin), tricyclic antidepressants (e.g., 
amitriptyline, nortriptyline, desipramine), a norepinephrine-serotonin reuptake inhibitor 
antidepressant (e.g., duloxetine), opioids (e.g., oxycodone, methadone, hydrocodone), 
and a dermal lidocaine patch as first- and second-line treatments for DPN. Among them, 
duloxetine and pregabalin have received U.S. Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) approval for DPN.
44, 45
 All of these medicines 
impact the pain pathway. Tricyclic antidepressants (TCAs) modulate the descending 
pain inhibition pathways of the brain stem and spinal cord primarily through inhibition 





 channels, α-adrenergic receptors, 
muscarinic-cholinergic receptors, and opioid receptors, which mediate hyperalgesia and 
allodynia.
46
 Earlier reports suggest that the tertiary amines (amitriptyline) have balanced 
serotonin and norepinephrine reuptake inhibition, and may have better efficacy for DPN 





Table 1.1 Pharmacotherapy in DPN Guidelines 
 
  TCAs Duloxetine Gabapentin Pregabalin Opioids  Lidocaine 
TEPDN 
(2011) 
1st line 1st line 1st line 1st line 2nd line - 
NeuPSIG 
(2010) 

















2nd line 2nd line 1st line 2nd line 3rd line 
TEPDN: Toronto Expert Panel on Diabetic Neuropathy; NeuPIG: Neuropathic Pain Special Interest Group; 
EFNS: European Federation of Neurological Societies; NICE: National Institute for Health and Clinical 




Table 1.2 Dosage Recommendation of Each Guideline 
 












  imipramine 
(25-75 mg/d) 
      oxycodone  
(20-80 mg/d) 
  
          morphine  








60 mg bid 1200 mg tid 200 mg tid tramadol  
(400 mg/d) 
3 patches 

































          oxycodone  
(120 mg/d) 
  
          morphine  
sulfate SR  
(120 mg/d) 
  
TEPDN: Toronto Expert Panel on Diabetic Neuropathy; NeuPIG: Neuropathic Pain Special Interest Group; 
EFNS: European Federation of Neurological Societies; NICE: National Institute for Health and Clinical 






clinical crossover trial conducted by Max et al. showed that the efficacy of desipramine  
was similar to amitriptyline.
47
 Additional comparative trials would be useful to 
differentiate tertiary and secondary amines, but it is hard to fund trials for a generic 
product. The secondary amines (desipramine) are useful alternatives in patients unable to 
tolerate the side effects of amitriptyline, which has higher anticholinergic effects (dry 
mouth, constipation, and urinary retention).
48
 Overall, the advantages of TCAs are once-
daily dosing, low cost, and treatment of depression, which is a common co-morbidity in 
DPN patients. Clinical trials showed TCAs have an equivalent analgesic effect on both 
depressed and nondepressed patients,
49,50
 and the doses of TCAs for DPN are one-half to 
one-third the antidepressant doses. However, TCAs should be used with caution in 
patients with cardiac conduction disturbances and ischemic heart disease.
43
 Duloxetine 
(serotonin norepinepherine reuptake inhibitor (SNRI)) is an FDA-approved medication 
for DPN, and it has consistently demonstrated efficacy in some patients as described in 
systemic reviews.
43
 The most common side effect of duloxetine is nausea, but if the 
treatment is initiated at 30mg/day and titrated up after one week to 60mg/day, the nausea 
occurs less frequently.
51
 The advantage of duloxetine over a TCA is that there is no 
caution for cardiovascular patients.
52
  
Gabapentin and pregabalin bind at the  α2-δ subunit voltage-gated calcium 
channel producing changes in neurotransmitter release, but pregabalin has a 6-fold higher 
binding affinity than gabapentin.
7
 Pregabalin is an FDA approved medication for DPN 
that can be given twice daily, and the dosage can be rapidly titrated compared to 
gabapentin, which has complicated, nonlinear pharmacokinetics and is administered three 





somnolence, peripheral edema, and dry mouth.
36
 Currently, pregabalin is markedly more 
expensive than generic gabapentin, but the patent for pregabalin will expire in 2018 at 
which time generics will make it less expensive. Even though there are few drug 
interactions for gabapentin and pregabalin compared to TCAs, doses must be reduced in 
patients with renal insufficiency.
49
  
Topical lidocaine and opioids are the other two first-line medications for DPN. 
The lidocaine patches provide local anesthesia in the outer layers of skin and muscle and 
are usually well tolerated with few systemic adverse effects. Typically, lidocaine patches 
are used when neuropathic pain is well localized.
49
 Opioids provide analgesia by acting 
as agonists at mu and kappa opioid receptors in the central nervous system. Tramadol has 
different mechanisms, which include being a weak opioid and a mixed SNRI. However, 
morphine, oxycodone, and tramadol all have shown efficacy in DPN. The main concerns 
of opioids are their long-term safety, including abuse potential, immunologic changes, 
hypogonadism, and opioid-associated hyperalgesia.
43
 The common adverse effects of 
opioids include respiratory depression, sedation, nausea, itching, and constipation.
49
 In 
conclusion, opioids are unique in providing immediate pain relief compared to other 
medicines. 
Number Needed to Treat (NNT) is an epidemiological measure used to assess the 
effectiveness of a healthcare intervention. The NNT provides an indirect comparison of 
efficacy, which is the reciprocal of the absolute risk reduction (ARR) which is the 
difference between the control group’s event rate and the experimental group’s event rate. 
Therefore, the ideal NNT is 1 meaning that everyone improves (≥50% pain reduction) 





patients who will experience at least a 50% reduction in pain. Finnerup et al.
53
 did a 
systemic review of the medications in DPN, and it showed the best medication for DPN 
was amitriptyline (NNT: 2.1),
50
 followed by nortriptyline (NNT: 2.5), morphine (NNT: 
2.5), oxycodone (NNT: 2.6), tramadol (NNT: 3.4), pregabalin (NNT:3.9),
54
 gabapentin 
(NNT: 3.9), and duloxetine (NNT: 5.2). However, these results are different from the 
Cochrane reviews.
55-59
 The Finnerup et al. report only includes studies published through 
April 2005, but the Cochrane review includes studies through 2014. The Cochrane review 
includes the studies in the Cochrane CENTRAL, MEDLINE, and EMBASE databases, 
and the authors also hand-searched unpublished data from ClinicalTrials.gov and the 
World Health Organization (WHO) International Clinical Trials Registry Platform.  The 
Cochrane review showed that duloxetine at 60 mg daily was effective in treating DPN in 
the short term, with a risk ratio (RR) for ≥ 50% pain reduction at 12 weeks of 1.73 (95% 
CI: 1.44- 2.08), and the related NNT was 5 (95% CI: 4- 7).
57
 Gabapentin at 1200 mg or 
more daily was significantly better than placebo for at least 50% pain relief in DPN (38% 
vs. 21%), and the related NNT was 5.9 (95% CI: 4.6- 8.3).
59
 Opioids were significantly 
better than placebo in treating neuropathic pain, with risk difference for ≥ 50% pain 
reduction of 0.17 (95% CI: 0.02-0.33, P =0.03), and the related NNT was also 5.9 but 
with a wider confidence interval (95% CI: 3.0-50.0).
58





 had no first- or second-tier evidence, but the third-tier evidence in 
individual studies indicated some improvement in pain relief with desipramine and 
imipramine compared with placebo. A 3-month third-party payer cost-utility analysis 
used decision model to estimate cost effectiveness of despramine 100mg/day, gabapentin 





result showed desipramine and duloxetine both were more effective and less costly. The 





1.3 The Inadequacy of Current Treatments 
 
DPN patients are commonly untreated or under-treated.  One UK cohort study 
conducted at ten outpatient pain clinics found that 79% of the neuropathic-pain patients 
suffered from their pain for at least one year before they visited the pain clinic.
61
 Another 
UK study reported that only 81.4% of DPN patients (n=4,317) were treated with 
medication, which means 18.6% were not treated.
25
  One mail-survey study used the S-
LANSS questionnaire to identify neuropathic pain. Of the 4,541 returned surveys, 8.9% 
of the cohort had neuropathic pain (n=399). Among them, 215 patients had S-LANSS 
scores over 12, but 117 of them received no neuropathic pain medication.
62
 That is to say, 
54.4% of the neuropathic-pain patients were not treated in this study.  
Admittedly, many DPN patients are unsuccessfully treated. Their pain is not well 
controlled even when they take the medications regularly. Mendell et al. reported that 
most DPN therapies produce only 30 to 50% pain reduction in 2003.
63
 In one prospective 
study about 75% of DPN patients reported pain of the same severity after five years, 
which showed that their pain was not controlled.
64
 One 2006 European survey reported 
that 82% of DPN patients had moderate or severe pain (the pain interference: 4.8±2.4), 
on a scale of zero to ten with zero meaning no pain and ten meaning pain as bad as the 
patient could imagine, while 47% of them had received the medicine for more than a year 
with good adherence by their own reports.
29





patients took two or more neuropathic-pain medications for at least three months, and 
their pain severity was still more than five. Also, ten patients had refractory neuropathic 
pain in that study: using four or more neuropathic medications for at least three months, 
poor quality of life, or having a pain severity more than five for more than six months.
62
 
Due to the unsuccessful treatment, patients reported disappointment in one US study: 
only 22.4% of DPN patients were satisfied with their medication, and only 23.1% 
reported it as effective.
22
   
The literature also reported that physicians do not always prescribe guideline-
suggested medications. The UK cohort study reported that duloxetine and venlafaxine 
were prescribed to fewer than two percent of DPN patients,
25
 which is not consistent with 
the NICE and EFNS guidelines that suggest use of duloxetine as a first-line treatment.
36, 
38
 A US study conducted by Gore et al. reported that 46.7% of 255 patients used non-
steroidal anti-inflammatory drugs (NSAIDs),
22
 a medication class with no proven 
efficacy for DPN.  
Lastly, many DPN patients stop or change their medicine, making it difficult for 
them to find a successful treatment. One survey reported 70% of providers prescribed 
medications three or more times before concluding treatment failure.
65
 It is also common 
for patients to discontinue the treatment, switch, or add on after the initial therapy. A 
Swedish Registry study (n=13,479) showed that only 10 to 20% of patients remained on 
their neuropathic pain treatment over the three years, and half of them discontinued their 
treatment during the first 47-160 days.
66
 About 24% of the neuropathy patients (n=2,220) 
received a second neuropathic-pain (Neup) drug after their first Neup drug, for which 





medicine within six months (11%), some of them switched to another medicine after six 
months (7.5%), and a few of them added another medication (5.4%). Pregabalin was the 
most common second Neup drug (31%), followed by amitriptyline (28%) and gabapentin 
(26%). Among non-Neup prescriptions, strong opioids (9%), NSAIDs (including aspirin), 
and acetaminophen (9%) were the most common drugs to be added on. Among mental-
health co-medications, benzodiazepines (10%) and SSRIs (8%) were the most common 




1.4 Rationale of Combination Pharmacotherapy 
 
Optimal combination pharmacotherapy has been defined by Gilron et al. as: “two 
effective analgesic drugs that have complementary analgesic actions and substantially 
different side-effect profiles associated with little overlap of side-effects, such that the 
side-effect profile is minimized and efficacy is maximized.”67 In other words, the best 
combinations are two medicines that result in maximal pain relief and minimal adverse 
effects. Mao et al. state that several types of drug combinations are currently available: “1) 
combination of drugs from the same drug class that differ in their pharmacokinetics (i.e., 
onset and duration of action), such as combination of immediate with extended release 
opioid analgesics, 2) combination of two or more drugs from different drug classes, such 
as a combination of opioid with TCA, and  3) combination of drugs delivered through 
different routes, such as combination of topical agent with oral agent.”68 Experts 
encourage DPN patients to use combination pharmacotherapy and the literature presents 
some rational reasons for using it: patients often cannot control their pain with mono-





and most DPN patients have multiple etiologies, which require multiple medications for 
control. 
DPN patients often do not achieve their pain control with mono-pharmacotherapy; 
it is therefore common to use more than one drug. In a questionnaire study conducted 
with 357 primary care healthcare providers in New England, it was found that 90% of the 
patients required two or more medications.
65
 Kozma et al. using the MarketScan database 
reported that among 8004 patients who took pregabalin, 3,956 (49%) of them received an 
opioid before and after their pregabalin prescription, and 1,580 (20%) of them received 
an opioid only after pregabalin prescription, 
69
 indicating that managing DPN with 
pregabalin alone is insufficient. The Gore et al. study reported on how DPN patients used 
medication in the week preceding the survey. On average, DPN patients took 3.8 
(SD=3.9) different types of prescription drugs and two OTC medications: 79.2% of them 
reported taking at least one prescription medication, 52.2% of them reported taking at 
least two, and 47.8% of them were using both prescription and OTC medications. The 
study also showed that the higher the pain severity, the more medicines were taken.
22
 The 
reason for taking multiple medications is the lack of specific and selective medications to 
alleviate DPN, and the effectiveness is often reduced by dose-limiting side effects.
45, 70
 
Overall, the clinical trials have shown that the maximum response to mono-
pharmacotherapy on DPN is only around 50%.  
The development of fully effective analgesic pharmacotherapy for DPN remains 
elusive. Four main obstacles in clinical pain research have been described in the 
literature.
71
 First, the process to determine neuropathic pain has not been standardized. 





the sensitivity (78-83%) and specificity (78-90%) of the questionnaire is not perfect.
72
 
Second, experiments to determine the mechanism of action for the drugs were done in 
animal models, but owing to interspecies differences, varying physiology, receptor 
distribution, and evoked responses, the result of the experiments cannot be fully applied 
to humans. That is to say, the pain experienced and the treatment response in animals 
often differs from that in humans. Third, a standardized way to collect and characterize 
the symptoms and the signs of each individual’s pain has not been defined.73  
A cohort study used the neuropathic pain symptom inventory (NPSI) 
questionnaire and quantitative sensory testing (QST) to collect the baseline responses of 
four neuropathic pain disorders: central post-stroke pain, post-traumatic peripheral pain, 
painful HIV neuropathy, and DPN. The results showed each etiology has several distinct 
neuropathic-pain sensory profiles.
74
 One multinational randomized controlled trial (RCT) 
also reported that DPN patients had varying sensory profiles,
75
 and the post hoc cluster 
analysis reported different sensory profiles leading to differential responses in duloxetine 
and pregabalin.
76
 Last, the population enrolled in clinical trials is usually not the same as 
in the real world. The landmark Institute of Medicine (IOM) report, Relieving Pain in 
America, addressed the fact that RCTs may not be the most appropriate way to evaluate 
new analgesic agents, because RCTs have detailed requirements for their study 
population; however, chronic-pain patients have diverse biological, psychological, 
demographic, social clinical characteristics.
77
 RCTs also often exclude elderly patients 
and those with co-morbid psychological disorders, multiple pain disorders, or those 
taking other pain medications. Furthermore, the time frame of RCTs is usually 4 to 14 





medicines that show efficacy in RCTs do not show effectiveness in the real world.  
Because DPN patients have more than one etiology, they will require more than 
one medicine to control it. Even though the fundamental etiology has not been 
determined, the symptom complex of DPN patients demonstrates that in order to treat the 
whole person, medicine needs to be prescribed in various ways; instead of a single 
approach, a personalized approach is required. Based on the pharmacology and 
mechanism approach, combination pharmacotherapy is rational. The treatment of 
neuropathic pain could include: (1) sodium channel blockers to reduce spontaneous and 
ectopic activity (e.g., lidocaine), (2) specific calcium channel blockers to counter nerve 
injury–induced changes in calcium channel subunit function (e.g., gabapentin, 
pregabalin), (3) SNRIs to facilitate endogenous antinociceptive signaling, and (4) 
minocycline to attenuate experimental pronociceptive microglial activation. Combination 
pharmacotherapy for pain management is recommended in the guidelines from the World 
Health Organization (WHO),
78
 American Pain Society (APS), and American College of 
Rheumatology (ACR). Also, an American Academy of Family Physicians (AAFP) report 
advocated that many neuropathic-pain patients will require rational combination 
pharmacotherapy to obtain pain relief.
79
  
Sequential treatment is commonly used in clinical practice, but it restricts 
exposure of patients to more than one drug initially and limits combination 
pharmacotherapy.
80
 One study showed that the sequential addition of oxycodone safely 
reduced neuropathic pain in DPN patients who were initially treated at the maximum 
tolerated dose (MTD) of gabapentin.
81
 Even though it is effective to use sequential 





simultaneous titration of two drugs. Although it is not possible to know which medicine 
is more effective, concurrent treatment (combination pharmacotherapy) has shown 
efficacy in treating DPN patients in RCTs. In a double blind, crossover trial, DPN and 
postherpetic neuralgia (PHN) patients had better pain relief with combination treatment 
than just gabapentin or nortriptyline alone.
82
 In another RCT, DPN or PHN patients also 
reported better pain relief with a gabapentin-morphine combination than either as a single 
agent, but the MTD of the gabapentin-morphine combination was also lower.
83
 A meta-
analysis involving 386 participants from two studies
81, 83
 demonstrated a statistically 
significant superiority of gabapentin plus opioid over gabapentin alone, but with more 




1.5 Gaps in the Evidence for Combination Pharmacotherapy  
with DPN Patients 
 
Even though at least 45% of the DPN patients used more than one medicine in 
clinical practice,
85
 only a few combination pharmacotherapy clinical trials have been 
published (Table 1.3). A Cochrane review that assessed combination pharmacotherapy in 
neuropathic pain only identified 11 high-quality randomized controlled trials (RCT) for 
DPN.
81-84, 86-92
 Most trials showed better efficacy with combination pharmacotherapy, but 
one RCT in patients with PHN or DPN did not detect a statistically significant difference 
between pregabalin-oxycodone (10mg/ day) combination and pregabalin alone. The 
reason might be that the mean duration of diabetes was longer in the pregabalin-
oxycodone combination than in the pregabalin group (4.5 years vs. 2.9 years), there were 
fewer females in the pregabalin-oxycodone group (33% vs. 52%), and the literature 
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in pain relief;  
SF-MPQ;  
† MPQ: McGill Pain Questionnaire; VAS: Visual analog scales; BPI-MSF: Brief Pain Inventory Modified Short Form; 
SF 36: Short form 36; PGIC: Patient global impression of change; NRS: Numerical Rating Scale; BS-11: Box Scale-11; 
AE: adverse events; Gab: gabapentin; Nort: nortriptyline; GTN: glyceryl trinitrate; APAP: acetaminophen; Mor: 





multicenter RCT did not show a statistically significantly difference in pain reduction 
between a duloxetine (60mg/day)-pregabalin (300mg/ day) combination and high-dose 
monotherapy (p=0.370); however, the duloxetine-pregabalin combination had better 
scores in the mean changes in pain relief and 50% pain reduction, and it is considered to  
be effective, safe, and well tolerated.
75
 Many experts, and the guidelines, recommend 





efficacy of different regimens.
68
 
A systematic review conducted by Gilron et al. suggested the need for future 
combination pharmacotherapy studies, in order to understand the pharmacokinetics and 
pharmacodynamic interactions between components of analgesic combinations, and to 
define the optimum dose ratio between components.
67
 Furthermore, Gilron et al.  
suggested improved methods of assessing the interaction of multiple concurrent analgesic 
drugs and their side effects.
67
 Because most combination pharmacotherapy studies only 
compare a combination of drugs (A+B) with one drug (e.g., A); it is necessary to 
incorporate the additional comparison of A+B with B alone to make the evaluation more 
complete and useful.
67
 For example, the study conducted by Agrawal et al. had four 
comparison groups: glycerol trinitate (GTN) spray/sodium valproate, GTN spray/placebo, 
placebo spray/sodium valproate, placebo spray/placebo, which showed the complete 
comparison between combination pharmacotherapy and mono-pharmacotherapy.
86
 
However, the study conducted by Freeman et al. only compared tramadol/acetaminophen 
with placebo,
87
 and although the reduced daily pain was statistically significant (p=0.001) 
between tramadol/acetaminophen and placebo, the effect of the tramadol or 
acetaminophen was not been examined in this study. 
No published observational studies have compared combination pharmacotherapy 
with mono-pharmacotherapy in DPN patients. To date, comparisons between 
combination pharmacotherapy and mono-pharmacotherapy have only included RCTs. 
However, there are some observational studies that compared medication usage, clinical 















Study Population All costs 
(Cost 
Difference) 











































































































































































  pre-index: 
1 year 









































TCAs (n=1528) $ 29,313* 






Pregabalin (n=2207) $ 33,284* 
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Three pharmaceutical industry-funded studies found that DPN patients who were 
initiated on duloxetine were less likely to have subsequent opioid use than standard care 
(TCAs, venlafaxine, gabapentin, and pregabalin).
94-96
 However, Margolis et al. had 
different findings: patients who initiated therapy with duloxetine or pregabalin had no 
significant difference in DPN-related analgesic medications.
100
 Because different 
pharmaceutical industry-funded studies showed different results, there may be a conflict 
of interest. However, all studies showed substantial medication burden and co-
morbidities in DPN patients, including musculoskeletal and neuropathic pain conditions. 
Most studies found that immediate-release opioids and NSAIDs were the most 
commonly prescribed medications after the first-line DPN medications.
95-97, 104
 Several 
studies compared healthcare costs of different first-line treatments. Gore et al.
21
 used 
Pharmetrics and Udall et al.
101
 used the MarketScan database to compare pregabalin with 
gabapentin, and both studies showed no statistically significant difference in all-cause 
costs.
21, 101
 However, Gore et al. reported greater pain-medication burdens with 
gabapentin than pregabalin,
21
 and Udall et al. observed the higher prescription costs in 
pregabalin than gabapentin.
101
 Again Gore et al.
93
 used Pharmetrics, and Burke et al.,
99
 
and Margolis et al.
100
 used MarketScan to compare pregabalin with duloxetine, and all 
studies showed no statistically significant difference in all-cause costs.
93, 99, 100
 However, 
Gore et al. found that there were higher medication costs with duloxetine than 
pregabalin.
93
 Zhao et al.,
94
 Wu et al.,
95
 and Chen et al.
96
 used MarketScan to compare 
duloxetine with standard of care (SOC), which as TCAs, venlafaxine, gabapentin, and 
pregabalin. All studies found that patients who initiated therapy with duloxetine had 







In conclusion, the all-cause cost is not statistically significantly different if only 
comparing a first-line agent with another first-line agent. Only one study compared the 
DDI costs between duloxetine and pregabalin; Johnston et al. used MicroMedex to 
measure DDIs and used the Contraindications and Warnings and Precautions sections to 
define drug-condition interactions (DCIs). Their result showed duloxetine users had 
higher DDI and DCI costs than pregabalin users
103
 (Table 1.4). 
Overall, even though it is essential to know the relationships between medications 
and the clinical characteristics or healthcare costs in DPN patients, evidence is lacking to 
provide an understanding of the relationships between combination pharmacotherapy and 
its treatment patterns, co-morbidities, and healthcare costs in DPN patients.  
 
1.6 Current Reimbursement for DPN Medications 
 
A web-based survey of 300 physicians reported that nearly one-third of doctors 
did not receive sufficient reimbursement for their diabetic care, and 83% of them reported 
that Medicaid reimbursement was inadequate, while 67% reported private insurance 
reimbursement was inadequate.
105
 Leichter et al. concluded that the current system 
rewards less-excellent providers and penalizes more-excellent ones, which means many 
insurers may attempt to “downcode” the corrected coding for diabetic care or audit the 
frequency with which individual providers bill at a high level of service.  
Not only is there a reimbursement hurdle, but there are also prescribing 
restrictions through either a prior authorization requirement or step therapy. Margolis et 
al. concluded that prior authorization (PA) was shown to effectively control access to 
pregabalin in both Medicaid and commercial health plan populations.
106, 107





Medicaid population, the restricted states included one large industrial state and one 
smaller rural state. The unrestricted states included two large industrial states and two 
smaller rural states. The PA in the Medicaid population study was associated with 
increased opioid use and significantly greater disease-specific costs.
106
 For the 
commercial health plans population, the restriction was shown to have no statistically 
significant differences in the use of nonpregablin medications, and there was no between-
group difference in disease-related healthcare costs.
107
 Suehs et al. examined the impact 
of the step therapy policy for pregabalin implemented by a large national health insurance 
provider, Humana, Inc. The restricted cohort demonstrated greater decrease in pregabalin 
utilization and increase in gabapentin utilization compared with the unrestricted cohort.
108
 
The three studies demonstrated that both PA and step therapy have impacts on the usage 
of pregabalin. 
The NICE guideline includes a cost-effectiveness Markov model to determine 
first-line treatment. The Markov model was based on two pain states: at least 50% pain 
reduction, or no pain reduction. For patients who experienced pain relief, they were 
assumed to remain on the drug and continue to get pain relief for the remainder of their 
lifetime. For patients who experienced pain relief and minor adverse events, they were 
assumed to have been titrated to the minimum dose that gives pain relief and would 
continue to experience the adverse events or require drugs to alleviate them for their 
lifetime. The compliance was assumed to be 100% at base case, but was lowered to 50% 
in sensitivity analysis. The resource use was estimated through expert opinion. In the 
model presented it is recommended to use duloxetine 60 mg/day and amitriptyline 75 





to use amitriptyline 75 mg/day when the willingness-to-pay (WTP) is £20,000. 
Mack et al. did a systemic review on the off-label use of gabapentin for DPN, and 
summarized that there are solid research reports on gabapentin usage, the fact that the 
FDA has not approved this drug for this usage should not affect health insurance 
companies paying for it.
109
 In the range of prices for DPN medications, according to 
Drugstore.com, pregabalin is the most expensive at $189.98 per month, followed by 
duloxetine at $170.99 per month. In contrast, gabapentin comes in at $18.99 per month, 
amitriptyline at $12.99 per month, and nortriptyline at $19.99 per month. Due to the fact 
that effectiveness of the DPN medications do not differ much, it is reasonable to start 






 recommend both 




 recommend using 
pregabalin but gabapentin as first-line.   
 
1.7 Objectives of the Study 
 
            This study has the following objectives:  
1. Quantify and describe newly-treated DPN treatment patterns, including 
which drugs were selected and in what sequence, discontinuation rates, and a 
count of the total classes of DPN medications used in the study period. Determine 
the types of combination pharmacotherapy in DPN among newly-treated patients. 
2. Describe the co-morbidities by mono-pharmacotherapy DPN patients and 
combination pharmacotherapy DPN patients.  






4. Compare healthcare costs between patients taking mono-pharmacotherapy 
and combination pharmacotherapy for DPN. 
            This study has the following hypotheses:  
1 Patients who take combination pharmacotherapy for DPN are less likely to 
discontinue, switch, or add on therapy than patients who take mono-
pharmacotherapy. 
2 People who take combination pharmacotherapy for DPN have more co-
morbidities than patients who take mono-pharmacotherapy. 
3 Demographics and clinical characteristics of DPN patients will affect the 
likelihood of receiving combination pharmacotherapy.  
4 DPN patients taking combination pharmacotherapy have lower medical 
costs than patients who take mono-pharmacotherapy.  
 
1.8 Significance of the Work 
As Torrance et al. reported, many neuropathic pain patients are untreated, under-
treated, or unsuccessfully treated.
62
 Among the different difficulties of managing DPN 
patients, this study focuses on the treated patients and guideline-suggested medication: to 
define the characteristics and optimal combination pharmacotherapy for newly-treated 
patients with DPN. 
Some guidelines conclude that it is insufficient to use mono-pharmacotherapy to 
treat DPN patients and recommend prescribing combination pharmacotherapy after the 
failure of the first treatment. However, there is limited evidence in RCTs and no evidence 





combination pharmacotherapy in DPN patients. Many questions are unanswered in this 
area: how many newly-treated DPN patients start with combination pharmacotherapy? 
What kind of newly-treated DPN patients will start with combination pharmacotherapy? 
What regimens do newly-treated DPN patients take? What medications are added-on or 
switched after the index medicine? How do the patient characteristics affect the treatment 
patterns, and how do the treatment patterns affect the healthcare costs? To answer those 
questions, the Inovalon database has been chosen as the study database. It is an 
innovative database that has not typically been used for this type of research. A detailed 
description of Inovalon is described in section 2.1.  
To identify the characteristics and optimal combination pharmacotherapy in 
newly-treated DPN patients, the hypothesis is made that patients who receive 
combination pharmacotherapy will have lower healthcare costs than patients who receive 
mono-pharmacotherapy. This also implies that to take combination pharmacotherapy 
initially will be more effective in terms of not changing treatment patterns for newly-









2.1 Data Sources 
 
 Inovalon was selected as the data source for this project. Inovalon is a healthcare 
technology company founded in 1998, and per year it is responsible for over 800 
Healthcare Effectiveness Data and Information Set (HEDIS) reports, which are a 
standardized set of performance measurements developed by the National Committee for 
Quality Assurance (NCQA) to evaluate consumer healthcare. For example, for 
comprehensive diabetes care, if the organization used correct diagnosis and procedure 
codes, submitted claims and encounter data in a timely manner, had the lab values (LDL, 
HbA1C, microalbuminuria) complete, the HEDIS score would be higher. Therefore, 
through the collection of the HEDIS reports, Inovalon has its own registry called Medical 
Outcomes Research for Effectiveness and Economics Registry (MORE
2
). In this registry 
there are 5.5 billion medical data events, 78 million unique members, 1,488,974 T1DM 
patients, and 6,977,181 T2DM patients. All the information is divided into five databases: 
patient demographics, claim diagnostic data, eligibility and enrollment data, pharmacy 
data, and cost data (Table 2.1).  
 Since data collection in Inovalon was for HEDIS, some data were only available 





Table 2.1 Data Dictionary 
 
Demographic 
Field Name Data Type Nullable  
Member ID Integer Not null 
DOB Date Not null 
Sex Character varying (1) Not null 
State Character varying (2) Null 
Zip Character varying (9) Not null 
RaceType  Character varying (2) Null 
EthnictyType  Character varying (2) Null 
Pharmacy 
Field Name Data Type Nullable  
Claim ID Bigint Not null 
InferredPersonID Integer  Not null 
InferredProviderID Integer Not null 
Claim Status  Character varying (1) Null 
FillDate Date Null 
FillDateThru Date Null 
NDC Character varying (20) Null 
NDC9 Character varying (20) Null 
DaysSupply Integer  Not null 
SupplyFlag Boolean Not null 
Billed  Numeric (19,4) Null 
Allowed  Numeric (19,4) Null 
Copay  Numeric (19,4) Null 
Paid  Numeric (19,4) Null 
Cost  Numeric 19,4) Null 
QuantityDispensed Character varying (50) Null 
Claim diagnostic code 
Field Name Data Type Nullable  
InferredPersonID Integer Not null 
DOS Date Not null 
DOSThru Date Null 
Claim ID Bigint  Not null 
CodeType Character varying (100) Not null 
OrdinalPosition Smallint Not null 
CodeValue Character varying (100) Not null 
Enrollment 
Field Name Data Type Nullable  
InferredPersonID Integer Not null 





Table 2.1 Continued 
Enrollment 
NewEffective Date Date Not null 
NewTermination Date Date Not null 
PlanEmployeeFlag (Medical Flag) Boolean Not null 
RxFlag (Rx Indicator) Boolean Not null 
NewPayerCode Integer Null 
NewProductCode Integer Null 
Claim cost 
ClaimID Bigint Not null 
InferredPersonID Integer Not null 
InferredProviderID Integer Not null 
ClaimStatus Character varying (1) Null 
Dos  Date Not null 
Dosthru Date Not null 
Billed Numeric (19,4) Null 
Allowed  Numeric (19,4) Null 
Copay  Numeric (19,4) Null 
Paid  Numeric (19,4) Null 
Cost  Numeric (19,4) Null 
DischargeStatus  Character varying (2) Not null 
Unitsofservice Integer Not null 
RxProviderFlag Boolean Not null 
PCPFlag Boolean Not null 
RoomBoardFlag Boolean Not null 
MajorSurgery Boolean Not null 
ExcludeFromDischarge Indicator Boolean Not null 




study, and the HbA1c value was available for only 28% of the patients, which meant the 
identification of the diabetes was based on the diagnostic codes, not lab values, and the 
study could not stratify patients by HbA1c. Table 2.1 shows the characteristics and the 
missing conditions in each variable. If there is “null” in the “Nullable” column, it means 






 The objectives of this study as discussed in detail in section 1.6 are to describe 
how the patient characteristics affect the treatment patterns, and how the treatment 
patterns affect the healthcare costs in DPN patients; therefore, prescriptions, co-
morbidities, and cost are the three main variables in the study. Inovalon includes all of 
these variables including prescription data for each patient, with National Drug Code 
(NDC) codes and prescription filled date, allowing us to define the treatment patterns and 
the time to discontinue, switch, or add on to the treatment. It also has ICD9 codes for me 
to identify the co-morbidities of DPN, and data on the cost enabling us to calculate the 
healthcare costs between different treatment groups.  
 Other than the Inovalon database, the following sources of data were considered: 
1) electronic medical records (EMR), 2) administrative claims, 3) integrated health 
systems, 4) national surveys, and 5) patient registries.
110
 Since treatment patterns and 
healthcare costs are the main outcomes in the study, an EMR without these two variables 
was not considered. For example, if patients move to a new location or switch to a new 
healthcare provider, the follow-up of the medications will not be continued, which is 
especially an issue with chronic pain patients who change providers often; therefore, it is 
problematic to track the medication data and the treatment patterns in EMR.  
Even though cost data are rich in administrative claim databases which are 
generated from providers’ and patients’ transactions with payers, accessing 
administrative claim databases costs around $60,000 to $80,000 and lower-cost options 
for unfunded projects involve an application process that is usually 1 year, well outside 
the timeline for this PhD dissertation. Another source considered was using integrated 





it combines the completeness and economic data of a claim data set with the rich clinical 
data found in an EMR. An example is the Veterans Health Administration (VA), but the 
population in the VA is not generalizable to the general population, and it would be in 
conflict with the objectives of the study, which is to look not only at veterans but the 
broader US population.  
The last source considered was using national surveys: the National Health 
Interview Survey (NHIS), and the National Health and Nutrition Examination Survey 
(NHANES) are examples. However, they do not have enough pain-related information. 
According to the questionnaire, the pain in the surveys is not stratified to acute, chronic, 
or persistent pain; therefore, it is hard to identify DPN patients in the surveys.  
Due to the considerations of each source, the Inovalon database became the most 
suitable choice for this dissertation. 
 
2.2 Study Subjects and Eligibility Criteria 
2.2.1 Identify DPN Patients 
The analysis period was from January 1, 2006 to December 31, 2013. The index 
date was the date of the first prescription filled for a DPN drug: duloxetine, pregabalin, 
gabapentin, TCAs (amitriptyline, desipramine, nortriptyline), opioids (tramadol, 
oxycodone, morphine, oxymorphone, methadone, levorphanol, hydrocodone, 
hydromorphone
 
), or any route lidocaine (Table 2.2). All medications were identified 
through NDC codes, and to be qualified as included prescriptions, each DPN medication 
had at least a minimum of a 60-day supply dispensed during the post-index period, and it  





Table 2.2 Medications Used for Managing DPN 




Duloxetine (Cymbalta)  
α2δ ligands (modulate 
voltage-gated  
calcium channels)  
Pregabalin (Lyrica), Gabapentin (Neurontin)  
TCAs (tricyclic 
antidepressants)  
Tertiary: amitriptyline (generic); secondary: 
desipramine (generic) and nortriptyline (generic) 
Opioids (act on μ 
receptors)  
Tramadol† (Ultram), oxycodone, morphine 
(generic), oxymorphone, methadone (Dolophine, 
Methadose), levorphanol (Levo-Dromoran), 
hydrocodone (in Vicodin, Lortab, etc.)    
hydromorphone (Dilaudid)  
Topical agents  lidocaine patches (Lidoderm)  
*Individual agents are listed alphabetically. SNRI = serotonin-norepinephrine 
reuptake inhibitors; TCAs = tricyclic antidepressants.  
†Tramadol also weakly inhibits serotonin and norepinephrine reuptake.  
 
written for 60 days, and are determined by the “DaysSupply” variable. 
Patients who initiated these DPN medications between July 1, 2006 and 
December 31, 2012 were identified. However, patients may have used these medications 
before January 1, 2006, but since it is not within the study period, these data cannot be 
examined. Selected patients were ≥18 years old (as of the index date), had continuous 
health plan enrollment during the 6 months before and 12 months after the index date 
(pre- and post-index), and had one or more medical service claims with an associated 
diagnosis code for ‘diabetes with neurological manifestations’ (ICD-9 CM 250.6x) or 
‘polyneuropathy in diabetes’ (ICD9-CM 357.2x) in the period 6 months prior to or up to 


























Patients were excluded from the analysis if they had a diagnosis for postherpetic 
neuralgia (PHN) (ICD9: 053.1X), fibromyalgia (ICD9: 729.1X), cancer (140.xx-172.xx, 
174.xx-208.xx, 235.xx-239.xx), post-trauma (ICD9: 338.11, 338.21), and postoperative 
disease (ICD9: 338.12, 338.22, 338.18, 338.28) at any time in the available data (because 
these patients might have received any of the DPN medications due to their non-DPN 
neuropathic pain). Patients were also excluded from the analysis if they were less than 18 
years of age on the index date, had no valid gender information recorded, or had any 
quantity of days’ supply for DPN medication claims that was negative or missing. 
 
2.2.2 Quantify Treatment Patterns 
This study evaluated DPN therapies with the following drugs: TCAs 
(amitriptyline, desipramine, nortriptyline), opioids (tramadol, oxycodone, morphine, 
7/1/2006               12/31/2012 Index date 
The first prescription 
fill during the  
identification period 
1 year follow-up 6 months pre-index 
Combination Pharmacotherapy 
Mono-pharmacotherapy No treatment 
For DPN 






oxymorphone, methadone, levorphanol, hydrocodone, hydromorphone), duloxetine, 
gabapentin, pregabalin, any route lidocaine, and the combinations of these drugs. In order 
to simplify the description for this dissertation, opioids are counted as one agent, and 
TCAs are also counted as one agent. Every patient in the study cohort was a newly-
treated patient; none of them had any study medicine prescriptions between 1/1/2006-
6/30/2006 or 6 months before the index date. The index date was defined by the first date 
documented as  using any of the study medicine, and the medicine used on the index date 
would be the index medicine. There were four treatment groups in this study: discontinue, 
nonswitch, switch, and add-on. Every group was mutually exclusive, and Figure 2.2 is the 

























Figure 2.2 The Algorithm for Defining Treatment Groups 
DC: discontinue; mono: mono-pharmacotherapy; combo: combination pharmacotherapy; 
med: medicine; d: days 
Exclude the prescriptions less than 60 days 
Determine the medications used for each patient during the study period 




Gap> 60 d: 
(mono DC) 
Calculate the time between index 
medicine and the second medicine 
Over 30 days:  
(Mono-
pharmacotherapy) 
Within 30 days: 
(Combination 
pharmacotherapy) 
Gap> 60 d: 
(mono DC) 
Gap> 60 d: 
(Combo DC) 
























Each group was defined as follows: 
1. Exclude the prescriptions less than 60 days.  
Each medicine needed to be taken at least 60 days to be included, since 
treatment for less than 60 days would not have a meaningful impact on the 
disease; this followed the criteria defined by Romanelli et al., who conducted a 
study to evaluate the medication compliance for patients who started with 
branded statins, and the prescriptions had to have at least two pharmacy claims 
to be included,
111
 which is a reasonable criterion for a chronic disease. 
Admittedly, Ziegler et al. concluded that the efficacy of DPN medication 
should be judged only after 2-4 weeks of treatment.
7
 Even though excluding 
the prescriptions less than 60 days in duration will inevitably exclude some 
patients who do no not have prescriptions longer than 60 days, in order to 
determine the optimal pharmacotherapy for DPN patients, the  
treatment needs to be at least long enough for possible efficacy. Therefore, any 
records with prescriptions of less than 60 days were excluded from this study. 
2. Determine the medications used for each patient during the study period. 
Patients could take TCAs, opioids, duloxetine, gabapentin, pregabalin, or any 
route lidocaine during the study period, or they might take any combination of 
two or more medicines during the study period. Determining the medications 
used for each patient during the study period was the first step to categorize the 
treatment group. There are eight treatment groups in this study: mono-
pharmacotherapy (nonswitch), mono-pharmacotherapy (discontinue), mono-





pharmacotherapy (nonswitch), combination pharmacotherapy (discontinue), 
combination pharmacotherapy (switch), combination pharmacotherapy (add-
on). If patients only took one medication through the study period, they were 
placed either into mono-pharmacotherapy (nonswitch) or mono-
pharmacotherapy (discontinue). If patients took two or more medications 
during the study period, they were grouped into other treatment groups. 
Therefore, patients who only used one medication during the study period 
without any treatment gaps were categorized into mono-pharmacotherapy 
(nonswitch). For example: 
a. The patient started using pregabalin from 9/25 till 2/2, and the 
prescription details are the following: 25Sep2007-25Oct2007; 
27Oct2007-26Nov2007, 03Dec2007-02Jan2008; 03Jan2008-
02Feb2008. 
Mono–pharmacotherapy (nonswitch)   
 
Therapy A 
        
 
Pre Pre Pre Pre Pre Pre 
 
  
    
 
Sep Oct Nov Dec Jan Feb 
       
3. Calculate the time between index medicine and the second medicine for 
patients with more than one medicine. 
In order to define the combination pharmacotherapy, the next step was 
calculating the time between index medicine and the second medicine. If the 
time between the second medicine and index medicine was within 30 days, 
then it was counted as combination pharmacotherapy. If the time between the 





counted as mono-pharmacotherapy. Therefore, the combination 
pharmacotherapy is defined as having two or more medications used within the 
first 30 days—not the entire study period. The reason for the restriction to the 
first 30 days is that the objective of this study is to determine the differences 
between combination and mono-pharmacotherapy in time to discontinue, 
switch, or add on. Therefore, the combination pharmacotherapy group needs to 
be defined during the index period. The study conducted by Suh et al. defined 
combination therapy as allowing a 15-day maximum interval between a statin 
fill and fibrate fill.
112
 However, considering the clinical aspect of DPN 
treatment as Ziegler et al. recommended that the efficacy of DPN medication 
should be judged after 2-4 weeks, for this study the interval was changed to 30 
days. If patients were on combination pharmacotherapy, their index medicine 
would change to the combination, which means the index medicine could be, 
for example, gabapentin and opioids, or gabapentin and TCAs.  
4. Define the discontinue groups. 
Patients would either have treatment gaps of their index medicine or not. 
Therefore, after defining patients on mono- or combination pharmacotherapy, 
the discontinue group is defined. Patients with a gap greater than 60 days 
during the study period would be defined as a discontinuation, and were 
classified into the discontinue group. Regardless of the subsequent drug 
therapy, if the patients had a 60-day gap of their index medicine, they would be 
placed into the discontinue group. The reason for choosing 60 days as a cut-off 
is from the Gore et al. study.
113





augmentation, and discontinuation of the treatment in patients with 
osteoarthritis and chronic low back pain, and the index therapy discontinuation 
was defined as a gap of over or equal to 60 days between the end of the 
previous prescription and the start of the next prescription.
113
 Therefore, if 
patients have a 60-day treatment gap of their index medicine, they will be 
placed into the discontinue group. Following are some examples: 
a. Patients who took one agent in the beginning, having a treatment gap 
after, were placed into the mono-pharmacotherapy (discontinue). For 
example, the patient took TCA from 8/23-9/22, had a gap of 215 days, 
and then had lidocaine on 4/25. The prescription details follow: 
23Aug2006-22Sep2006 (TCA); 25Apr2007-25May2007 (Lido), 
06Jun2007-015Jul2007 (TCA); 12Jul2007-11Aug2007 (Lido).  
Mono-pharmacotherapy (discontinue) 
  
> 60 day gap 
       
 
TCA   
    
  
  
TCA   
 
              Lido     Lido 
 
Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul 
 
b. Patients who took two agents in the beginning, then had a treatment gap 
of their two agents after, were placed into the combination 
pharmacotherapy (discontinue). For example, the patient took 
pregabalin and gabapentin from 11/13-12/13, and then only pregabalin 
till 2/2, which means the patient had a treatment gap of pregabalin and 
gabapentin since 12/13. The prescription details follow: 13Nov2007-





02Feb2008 (Pre); 15May2008-14Jun2008 (Pre).  
Combination Pharmacotherapy (discontinue) 
 
  > 60 day gap 
  
 




Pre Pre Pre     Pre 
 
Nov Dec Jan Feb Mar May 
 
5. Categorize switch and add-on. 
After defining the discontinue group, only the groups of switch and add-on 
needed to be defined. If patients continued the index prescription until the end 
of the follow-up, then any second medicines would be counted as a medicine 
that was add-on. If patients discontinued the index medicine before the end of 
the follow-up, then the second medicine would be counted as a medicine that 
was a switch. The definition is aligned with Gore et al., “Therapy switching 
was defined as a prescription for another medication class within 60 days 
before or after the date of discontinuation of index therapy. Therapy 
augmentation was defined as a prescription for another medication class > 60 
days before the date of discontinuation or end of follow-up.”113 In other words, 
the main difference between patients who switch and add on to the treatment is 
whether they continue the index medicine to the end of the follow-up or not. 
Following are examples of both groups in mono-and combination 
pharmacotherapy. 
a. Patients who took one agent in the beginning, started another agent, and 
discontinued the index medicine to the end of the follow-up were 





patient started with gabapentin on 5/21, and then switched to pregabalin 
on 8/16. The prescription details follow: 20May2010-19Jun2010 (Gab); 
21Jun2010-21Jul2010 (Gab); 17Jul2010-16Aug2010 (Gab); 
16Aug2010-15Sep2010 (Pre+ Gab); 21Sep2010-21Oct2010 (Gab); 




Therapy A Therapy B 
  
 
Gab Gab Gab Gab Gab Gab   
 
      Pre     Pre 
 
May Jun Jul Aug Sep Oct Nov 
 
b. Patients who took one agent in the beginning, started another agent, and 
continued the index medicine to the end of the follow-up, were placed 
into the mono-pharmacotherapy (add-on). For example, the patient 
started with gabapentin on 11/16 and then added on lidocaine on 3/30. 
The prescription details follow: 16Nov2011-16Dec2011 (Gab); 
10Dec2011-09Jan2012 (Gab); 10Jan2012-24Feb2012 (Gab); 
02Mar2012-01Apr2012 (Gab); 30Mar2012-29Apr2012 (Gab+ Lido); 
26May2012-19Jun2012 (Gab); 20Jun2012-20Jul2012 (Gab+ Lido); 





Gab Gab Gab Gab Gab Gab Gab Gab Gab Gab 
 
          Lido     Lido   
 
Nov Dec Jan Feb Mar Apr May Jun Jul Aug 
 
a. Patients who took two agents in the beginning and discontinued the 





combination pharmacotherapy (switch). For example, the patient started 
with pregabalin and TCAs on 11/22, and then switched to pregabalin 
and duloxetine on 12/3.The prescription details follow: 27Oct2010-
21Nov2010 (Pre); 22Nov2010-02Dec2010 (Pre+ TCAs); 03Dec2010-
18Jan2011 (Pre+ TCAs+ Dul); 19Jan2011-24Feb2011 (Pre+ Dul); 
25Feb2011-22Mar2011 (Dul)  
Combination Pharmacotherapy (switch) 
  
 
Pre Pre Pre Pre 
        
 
TCA TCA Dul Dul Dul 
       
 
   Dul 
 
    
       
 
Nov Dec Jan Feb Mar 
        
b. Patients who took two agents in the beginning, started a new agent, and 
continued the index medicine to the end of the follow-up, were placed 
into the combination pharmacotherapy (add-on). For example, the 
patient started with pregabalin and gabapentin on 12/11, and then added 
duloxetine on 6/3. The prescription details follow: 11Dec11-
04Mar2008 (Pre+ Gab); 07Mar2008-05Jun2008 (Pre+ Gab); 
03Jun2008-02Aug2008 (Dul+ Pre+ Gab). 
Combination Pharmacotherapy (add-on) 
 
Pre Pre Pre Pre Pre Pre Pre Pre Pre 
 
Gab Gab Gab Gab Gab Gab Gab Gab Gab 
 
            Dul Dul Dul 
 
Dec Jan Feb Mar Apr May Jun Jul Aug 
 
c. More examples of the switch group: patients might switch from one 
medicine to two medications. For example, the patient started with 





4/21. The prescription details follow: 21Nov2007-21Dec2007 (Pre); 
17Dec2007-16Jan2008 (Pre); 23Feb2008-24Mar2008 (Pre); 
21Apr2008-21May2008 (Opi+ Gab); 24May2008-23Jun2008 (Opi+ 




Pre Pre Pre 
         
     
Gab Gab Gab Gab 
    
 
         Opi Opi   Opi Opi  
    
 
Dec Jan Feb Mar Apr May Jun Jul 
     
6. The rest of the patients are in the combination pharmacotherapy nonswitch 
group. 
For patients who used more than two medications during study period, after 
defining the groups of discontinue, switch, or add-on, the rest of the patients 
are placed into combination pharmacotherapy (nonswitch). 
a. Patient started with pregabalin + duloxetine on 5/25/2007 till 4/2/2008. 
The prescription details follow: 02May2007-18May20007 (Dul); 
25May20007-23Aug2007 (Pre+Dul); 27Aug2007-26Sep2007 (Dul); 
04Oct2007-02Jan2008 (Pre+Dul); 03Jan2008-02Apr2008 (Pre+ Dul) 




Pre Pre Pre 
 
Pre Pre Pre Pre Pre Pre 
 
Dul Dul Dul Dul Dul Dul Dul Dul Dul Dul 
 
Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar 
7. After the treatment group is categorized, additional changes were not 
considered.  
For the objectives of this analysis, only the first change of the treatment 





the following sequences were not considered: changing the add-on medicine, 
switching to another medication after adding-on, for example, the patient 
started with a TCA on 3/2, and then added on an opioid on 4/18. Even though 
the patient also added on lidocaine on 8/2, it was not considered in this study. 
The prescription details follow: 02Mar2010-18Apr2010 (TCAs); 19Apr2010-
19May2010 (TCAs+ Opi); 09Jun2010-29Jun2010 (Opi); 30June2010-
01Aug2010 (TCAs+ Opi); 02Aug2010-01Sep2010 (TCAs+ Opi+ Lido); 
27Sep2010-24Oct2010 (TCAs+ Opi+ Lido); 25Oct2010-25Nov2010 (TCAs); 
26Nov2010-10Dec2010 (TCAs+ Opi); 11Dec2010-26Dec2010 (TCAs+ Opi+ 
Gab); 03Jan2011-02Feb2011 (Gab) 
  
Prescriptions were not considered after  
the first sequence 
 
Therapy A Therapy A+B 
 
TCA TCA TCA   TCA TCA 
 























          Lido 
 
Lido       
  
 
Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan 
   
 
2.3 Outcome Measures 
The endpoints of this study were patient distribution in different DPN agents 
among different treatment groups during the study period. All regimens for the new users 
with mono-pharmacotherapy and combination pharmacotherapy in DPN patients during 
2006 to 2012 were captured and categorized into four groups: discontinue, nonswitch, 
switch, and add-on. Time to discontinue, time to switch, and time to add on the treatment 









Time to discontinue 
    
 
TCA TCA   
    
  
  
TCA   
 
                Lido     Lido 
 
Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul 
 
Time to switch was calculated as the number of days from the index date to the first 
prescription fill date of the switched medicine.  
  
 
Time to switch 
      
 
Gab Gab Gab Gab Gab Gab   
     
 
      Pre     Pre 
     
 
May Jun Jul Aug Sep Oct Nov 
      
Time to add on was calculated as the number of days from the index date to the first 
prescription fill date of the add-on medicine. 
     
Time to add on 
    
 
Gab Gab Gab Gab Gab Gab Gab Gab Gab Gab 
   
 
          Lido     Lido   
   
 
Nov Dec Jan Feb Mar Apr May Jun Jul Aug 
     
 Other endpoints of this study were the predictors that newly-treated DPN patients 
would receive combination pharmacotherapy, the odds-ratio of the likelihood to receive 
combination pharmacotherapy, and the co-morbidities and healthcare costs in both mono- 
and combination pharmacotherapy groups. The cost data were inflated to 2012 using the 
US consumer price index for medical care.
114
  There were 7 people who had mean costs 
higher than $1,000,000 during the post-index period. Therefore, the highest 0.25% 
outliers was replaced as missing; patients who had mean costs higher than $1,001,838 





2.4 Independent Variables 
 The dependent variables represent the outputs or effects, and the independent 
variables represent the inputs or causes. The dependent variables of this study were 
defined as whether the patients were using combination pharmacotherapy on the index 
date or not. And the independent variables of this study were age, gender, region, and the  
insurance plan, which were determined on the index date. Insurance plan was classified 
as: Commercial, Medicaid (Children’s Health Insurance program (CHIP), Medicaid 
disabled, Medicaid low income, Medicaid restrict), Medicare (Special needs plan-chronic 
condition, Special needs plan-dual eligible, Special needs plan-institutionalized, 
Medicare cost, Medicare risk), and Self-Insured.  
Regions included all 50 states and the District of Columbia and Puerto Rico, and 
were classified as the following: West (Arizona, Colorado, Idaho, New Mexico, Montana, 
Utah, Nevada, Wyoming, Alaska, California, Hawaii, Oregon, Washington), Midwest 
(Indiana, Illinois, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, 
Nebraska, North Dakota, South Dakota), Northeast (Connecticut, Maine, Massachusetts, 
New Hampshire, Rhode Island, Vermont, New Jersey, New York, Pennsylvania), South 
(Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina, South 
Carolina, Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, 
Louisiana, Oklahoma, Texas), and Puerto Rico.
115
  
 Co-morbidities are another independent variable and described in both pre- and 
post-index periods.
93
 The pre-index co-morbidities were identified in pre-index period, 
and post-index co-morbidities were identified in post-index period. The pre-index period 





and the follow-up period was 1 year after the index date. The ICD-9 code of each co-
morbidity is displayed in Table 2.3.  
 
2.5 Data Analysis 
2.5.1 Descriptive Statistics 
Stata SE v. 13 (StataCorp, College Station, Tx) and SAS 9.3 were used for 
statistical analysis. Descriptive statistics were used to describe DPN treatment patterns 
and distributed into the discontinue group, the nonswitch group, the switch group, or the 
add-on group. The healthcare costs were reported in mean, median, interquartile range 
(IQR) for each group, and the costs were used to compare between patients with and 
without combination pharmacotherapy.  
Numbers of co-morbidities were categorized into three groups: patients who had 
one to four co-morbidities, five to seven co-morbidities, and above seven co-morbidities. 
These groups were selected since the median of co-morbidities were five in pre-index, 
and the median of co-morbidities were seven in post-index. The co-morbidities were also 
categorized into different disease groups.  If patients had myocardial infraction, 
congestive heart failure, peripheral vascular disease, cerebrovascular disease, coronary 
heart disease, hypertension, or hyperlipidemia, then they would be classified as having a 
cardiovascular disorder. If patients had retinopathy, or nephropathy, then they would be 
classified as having a diabetes-related condition. If patients had depression, bipolar  
disorder, or anxiety, then they would be classified as having a mental disorder. If patients 
had insomnia, then they would be classified as having as a sleep disorder. If patients had  







Table 2.3 ICD-9 Codes of the Co-morbidities 
Disease ICD-9 Codes 
Cardiovascular disorders  
Congestive heart failure 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 
404.13, 404.91, 404.93, 425.4-9, 428.x 
Peripheral vascular disease 093.0, 437.3, 440.x, 441.x, 443.1-443.9, 447.1, 557.1, 
557.9, v43.4 
Cerebrovascular disease 362.34, 430.x-438.x 
Coronary heart disease 410.xx-414.xx 
Hypertension 401.x 
Hyperlipidemia 272.0, 272.1, 272.2, 272.4 
Diabetes-related conditions  
Retinopathy 362.01, 362.02 
Nephropathy 582.xx, 583.0-4, 583.6, 583.7, 585, 586, 588.0, 588.1, 
588.8, 588.9 
Chronic renal failure 585.xx 
Mental disorders  
Depression 296.2x, 296.3x, 300.4, 311 
Bipolar disorder 296.4x, 296.5x, 296.6x, 296.7 
Anxiety 300.00, 300.5, 300.09, 300.20, 300.20, 300.22, 300.23, 
300.29, 300.3, 308.3 
Sleep disorders  
Insomnia/sleep disorders 780.5x, 307.4x, 347.0x, 347.1x, v69.4 
Musculoskeletal pain conditions  
Arthritis and other arthropathies 711.xx, 712.xx, 713.x, 714.4x, 714.8x, 714.9x, 716.xx, 
717.xx, 718.xx, 719.xx 
Rheumatoid arthritis 714.0, 714.1, 714.2 
Low back pain 720.1x, 721.3x, 721.9x, 722.1x, 724.02, 724.2x, 724.5x, 
724.8x, 733.02 
Back and neck pain, other than 
low back pain 
720.81, 720.89, 720.9, 721.0, 721.2, 721.5-721.9, 722.11, 
722.30, 722.31, 722.39, 722.4, 722.6, 722.80-722.82, 
722.90-722.92, 723.x (except 723.4), 724.01, 724.1, 
724.8, 724.9, 737.10-737.12, 737.19-737.22, 737.29, 
737.30, 756.10, 756.13-756.17, 756.19, 805.8, 847.9  







or rheumatism, then they would be classified as having a musculoskeletal pain condition. 
 
2.5.2 Bivariate Analyses of Demographics 
Distribution of age, gender, region, insurance type, and the number of co-
morbidities were compared between patients with and without combination 
pharmacotherapy. Gender, region, insurance type, and the co-morbidities are categorical 
variables and were normally distributed in this study, so the Pearson’s chi-square test was 
used. Age was a continuous variable and was normally distributed in this study, so the 
Student t-test was used. The pre-index and post-index enrollment days were continuous 
variables and were nonparametric distributed in this study, so the Wilcoxon Mann- 
Whitney test was used.  
The proportions of the treatment groups were not normally distributed and were 
being compared among six index medications, so the Kruskal Wallis test was used. The 
healthcare costs were not normally distributed and were being compared between patients 
with and without combination pharmacotherapy, so the Wilcoxon Mann-Whitney test 
was used. 
 
2.5.3 Kaplan-Meier Analysis 
The continuation of mono- and combination pharmacotherapy is being 
calculated through Kaplan-Meier survival function. The time to switch or add on 
to another medication in either mono- or combination pharmacotherapy was also 
calculated through Kaplan-Meier survival function. 





combination pharmacotherapy, each patient was followed until either the time that 
the combination pharmacotherapy was discontinued or the end of the follow-up. 
The cumulative survival function Ŝ[t] is the proportion of subjects who continued 
the combination pharmacotherapy at time t. The probability that a patient 
continued the mono-pharmacotherapy the first t days is the joint probability of 
continuing days. This probability was estimated by Ŝ(t)=p1p2p3….pt. If there were 
no discontinuation, the probability (p) would equal one on all days, and this 
estimate is called the Kaplan-Meier survival function.  
The Kaplan-Meier survival function was calculated for the combination 
pharmacotherapy, where pk1 is the probability of continuing the combination 
pharmacotherapy on the k
th
 day on which discontinuation occurred, and the 
equation is below: 
 
         
         
 
 
The pk2 is the probability of continuing the mono-pharmacotherapy on the 
k
th
 day on which discontinuation occurred, and the equation is below:  
 
         







The Kaplan-Meier survival function was not only determined for the 
treatment discontinuation, but also the time to switch or add on another 
medication in both mono- and combination pharmacotherapy. The same treatment 
patterns were also determined in the six index medicines in the mono-
pharmacotherapy group. 
 
2.5.4 Simple Proportional Hazards Model 
The hazard function λ[t] is the instantaneous rate per unit time at which 
people were discontinued at time t. λ[t] = 0 implies that there was no risk of 
discontinuation. Large values of λ[t] implies a rapid rate of decline in S[t].  
 
     




Hazard ratio (R) is the risk (discontinuation) of combination pharmacotherapy at 
time t relative to mono-pharmacotherapy. The equation for the hazard ratio of the 
combination pharmacotherapy discontinuation is as follows: 
 
                                
                        
 
                           
                        






Simple hazard regression model was used to calculate the relative risk of 
discontinuation, switch, and add-on associated with patients who used combination 
pharmacotherapy. The reference group was mono-pharmacotherapy, and    is the relative 
risk (discontinuation) of combination pharmacotherapy relative to mono-
pharmacotherapy, and the equation is below: 
 
                                
  [t]   /                       [t]  =  
   
 
A 95% confidence interval for this relative risk was Ŕexp[±1.96 x se [β]]. If two 
treatments were equally effective, the relative risk would be one, and β would be zero. 
Below is the regression model for the risk of discontinuation in combination 
pharmacotherapy:  
 
                             [t]=                       [t] exp[β (groupxi )] 
 
For mono-pharmacotherapy patients, TCAs was the reference medicine, since it is 
proven to be effective and inexpensive. The hazard ratio of opioids discontinuations 
compared to TCAs was calculated, and the equation is below:  
 
            
        
 
           
        





The following hazard ratio were also calculated: duloxetine vs. TCAs, gabapentin 
vs. TCAs, pregabalin vs. TCAs, and lidocaine vs. TCA. Simple hazard regression model 
was not only used to calculate the relative risk of discontinuation, switch, and add-on 
associated with patients who used combination pharmacotherapy, but was also used to 
calculate the relative risk of the patterns associated with patients who used opioids, 
duloxetine, gabapentin, pregabalin, or any route lidocaine, and the reference group were 
the patients who used TCAs. 
 
2.5.5 Multiple Logistic Regression 
For each model, the dependent variable was a dichotomous indicator coded as “1” 
for patients in the combination cohort, and “0” for patients with mono-pharmacotherapy. 
Age, gender, insurance plan type, region, and the numbers of co-morbidities were 
covariates that measured on the i
th
 patient. Table 2.4 is one of the odds ratio tables in this 
study. The covariate in Table 2.3 is co-morbidities, and the patients can be grouped into 
with or without co-morbidities.  
The odds ratio is measured by the Mantel-Haenszel estimate, and it means the 
odds of the patients to use combination pharmacotherapy in the certain co-morbidity. 
 
Table 2.4 Odds Ratio Table 
 Co-morbidity (yes) Co-morbidity (no) Total 
Combination 
pharmacotherapy 
d1j d0j m1j 
Mono-
Pharmacotherapy 
c1j c0j m0j 
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The first model in our study was to test the relationship between age, sex, 
insurance type, region, the numbers of co-morbidities and the chance to be in 
combination pharmacotherapy in all patients. The proposed equation was: 
 
logit[E[di| xi]]= α+ β1 [age categories] + β2[insurance type]+ β3[sex] + β4[regions] + β5 
[co-morbidities categories] 
 
The second model was to test the relationship between each co-morbidity and the 
chance to be in combination pharmacotherapy in all patients. The proposed equation is: 
 
logit[E[di| xi]]= α+ β1 [myocardial infraction] + β2[congestive heart failure]+ 
β3[peripheral vascular disease] + β4[cerebrovscular disease] + β5 [coronary heart disease] 





[depression] + β11[bipolar disorder] + β12 [anxiety] + β13 [insomnia] + β14 [arthritis and 
other arthropathies]+ β15 [rheumatoid arthritis] + β16 [low back pain] + β17 [back and next 
pain] + β18 [rheumatism]  
 
The third model was to test the relationship between cardiovascular disorders, 
diabetes-related condition, mental disorders, sleep disorders, musculoskeletal pain 
conditions and the chance to be in combination pharmacotherapy in all patients. 
The proposed equation was: 
 
logit[E[di| xi]]= α+ β1 [Cardiovascular disorders] + β2[Diabetes-related condition]+ 
β3[Mental disorders] + β4[Sleep disorders] + β5 [Musculoskeletal pain conditions] 
 
To interpret the result, exp [β1] was the combination pharmacotherapy odds ratio 
in myocardial infraction compared with mono-pharmacotherapy adjusted for other co-
morbidities. If the model covariates had no effect on the response variable, then all of the 
β parameters associated with the covariates would equal zero. The probability of di=1 
given the covariates xi was denoted o[xi1, xi2,…, xiq]=o[xi] and equals E[di| xi] 
Then the multiple logistic regression model assumed that di has a Bernoulli 
distribution. Not like single logistic regression model, the multiple logistic model 
includes more than one covariate. Pearson chi-square goodness-of-fit test was used to 
determine whether the model gives a good fit to data. Because all the covariates in the 









The residual for the j
th 
covariate pattern is dj- nj ô j. Substituting ô j for oj in the 
Equation gives the Pearson residual, which is  
 
   
       
           
 
 
If model is correct and nj is sufficiently large, then the equation below will have a 
chi-squared distribution with J- (q+1) degrees of freedom. The equation is the Pearson 
chi-squared goodness-of-fit statistic. It can be used as a goodness-of-fit test of model as 
long as J, the number of distinct covariate patterns, is small in comparison with the 
number of study subjects. A conservative rule of thumb is that the estimated expected 
number of events nj ô j should be at least 5 and not greater than nj – 5 for each distinct 
pattern of covariates. In this case we can reject model if the p-value associated with the 
chi-square is less than 0.05. 
  










3.1 Study Cohort 
 
There were approximately 59 million patients in the Inovalon database during 
2006-2013. The first screening was done by Inovalon, with inclusion criteria consisting 
of at least 2 diagnosis codes of DPN (ICD9 code: 250.6x or 357.2x), having 18 months 
continuous enrollment, age and gender information, and with prescriptions for one or 
more of the following: TCAs, opioids, duloxetine, gabapentin, pregabalin, or lidocaine. 
Approximately 170,000 patients met the above criteria, which exceeded the amount of 
data Inovalon would provide for a thesis project; therefore, 100,000 patients were 
randomly selected. The randomization process was by a computer through choosing 
among the100,000 ID numbers that were assigned by Inovalon.  
The distribution of the patients is presented in Figure 3.1. Of the 100,000 baseline 
patients, 72,614 of them have at least one 60-day or longer prescription for DPN after the 
index date, and there are 32,400 patients with 6-month pre-index and one-year post-index 
enrollments. Out of these, 7,566 patients have a DPN diagnosis code without PHN, 
fibromyalgia, cancer, post trauma, or post operative disease. Among them, 7,145 patients 
use mono-pharmacotherapy, which means they use one medicine on the index date, and 











































¥ Index date: the first prescription fill for DPN drug during the identification period 
 




Age ≥ 18 at index date¥  
N=70,681 
Combination Pharmacotherapy  
N=421 
 
Patients who have at least 1 year enrollment after index date 
N=54,617 
Patients who have at least 6 months enrollment before index date 
N=32,400 
Do not have PHN, fibromyalgia, cancer, post-trauma, post-
operative in study period 
N=20,299 




Patients with the following 
1. Prescription fill for duloxetine or pregabalin or gabapentin or TCAs or Opioids, or Lidocaine 
patches during 6/30/2006-12/31-2013 and  
2. age or gender information and  
3. 18 months continuous enrollment during 1/1/2006-12/31/2013 and 
4. 2+ diagnosis codes (ICD9: 250.6x or 357.2x) regardless of the time period during 2006-2013 
N= 170,000; Randomly selected 100,000 patients 
 










medicines within 30 days from the index date. 
 
3.1.1 Availability of HbA1c, Provider, and Costs in this Study Cohort 
The provider information and HbA1c value were also captured in this study; 
however, due to the proportions of missing data on these two variables, they were not 
used for the analysis. Table 3.1 and Table 3.2 are the details of these two variables. 
Due to the limited data for patients with costs, the characteristics of the patients with 
available cost data were examined. Table 3.3 shows 2,361 patients with mono-
pharmacotherapy (36.8%) and 150 patients with combination pharmacotherapy have cost 
information (39.4%). Patients who are self-insured have zero missing in cost data, and 
patients who have commercial insurance have more missing (68.8%) than Medicaid  
 








(HbA1c ≤7)  
Poor Control 
(HbA1c >7)  
Mono-pharmacotherapy  2066 (28.9%)  7.65± 1.76  7.15  963 (46.6%)  1103 (53.3%)  
Combination 
pharmacotherapy  92 (21.9%)  7.60± 1.96  7.05  46 (50%)  46 (50%)  
 





  Primary Care
‡
  Other specialty  Missing  Total  
Mono-pharmacotherapy  45 (0.6%) 329 (4.6%) 201 (2.8%)  6270 (87.8%)  7145  
Combination 
pharmacotherapy  3  (0.7%) 45 (10.7%) 10 (2.4%) 363 (86.2%) 421  
† Neurological surgery, Psychiatry & Neurology 








Table 3.3 Availability of Costs by Patient Characteristics 
  Missing ≤$400 $400<X<$500,000 >$500,000 Total 
Mono-pharmacotherapy 4517 63.22% 344 4.81% 2276 31.85% 6 0.08% 7145 
Combination  
pharmacotherapy 255 60.57% 10 2.38% 158 37.53% 0 0.00% 421 
18-44 278 63.33% 15 3.42% 146 33.26% 0 0.00% 439 
45-64 2069 63.02% 142 4.33% 1068 32.53% 4 0.12% 3283 
≥65 2425 63.09% 197 5.12% 1220 31.74% 2 0.05% 3844 
Male 2187 63.78% 170 4.96% 1069 31.18% 3 0.09% 3429 
Female 2585 62.48% 184 4.45% 1365 32.99% 3 0.07% 4137 
Commercial  1152 68.82% 78 4.66% 444 26.52% 0 0.00% 1674 
Medicaid 512 44.48% 40 3.48% 598 51.95% 1 0.09% 1151 
Medicare 2588 61.93% 228 5.46% 1358 32.50% 5 0.12% 4179 
Self-Insured 0 0.00% 1 8.33% 11 91.67% 0 0.00% 12 
Missing 520 94.55% 7 1.27% 23 4.18% 0 0.00% 550 
West 801 72.49% 76 6.88% 228 20.63% 0 0.00% 1105 
Midwest 1026 79.91% 33 2.57% 225 17.52% 0 0.00% 1284 
Northeast 735 46.49% 80 5.06% 765 48.39% 1 0.06% 1581 
South 1881 63.59% 143 4.83% 929 31.41% 5 0.17% 2958 
Puerto Rico 134 31.60% 21 4.95% 269 63.44% 0 0.00% 424 
Missing 195 91.12% 1 0.47% 18 8.41% 0 0.00% 214 
With 1-4 comorbidities 755 64.75% 103 8.83% 308 26.42% 0 0.00% 1166 
With 5-7 comorbidities 2143 63.22% 167 4.93% 1078 31.80% 2 0.06% 3390 
With >7 comorbidities 1874 62.26% 84 2.79% 1048 34.82% 4 0.13% 3010 
2006 1029 87.87% 44 3.76% 98 8.37% 0 0.00% 1171 
2007 1226 71.82% 55 3.22% 426 24.96% 0 0.00% 1707 
2008 542 47.29% 76 6.63% 528 46.07% 0 0.00% 1146 
2009 825 69.39% 34 2.86% 329 27.67% 1 0.08% 1189 
2010 602 64.04% 41 4.36% 295 31.38% 2 0.21% 940 
2011 378 45.76% 62 7.51% 384 46.49% 2 0.24% 826 







(44.5%) and Medicare (61.9%). Patients who live in Puerto Rico have less missing 
(31.6%) in cost data, and patients who live in the Midwest have more missing (79.9%) 
than those living in the West (72.5%), South (63.6%), and Northeast (46.5%). Year 2006  
has a lot more missing data (87.9%) compared to year 2012 (29.0%).  
 
3.1.2 Demographic Characteristics of DPN Patients 
There were 7,145 patients with mono-pharmacotherapy and 421 patients with 
combination pharmacotherapy. Patients in the mono-pharmacotherapy group were older 
than patients in combination pharmacotherapy group by around four years (64.6± 11.7 vs. 
60.6±11.5 p<0.001). Both the mono- and combination pharmacotherapy group had more 
females than males, but it was not statistically significantly different (p=0.111). More 
mono-pharmacotherapy patients used Medicare insurance compared to combination 
pharmacotherapy patients (56% vs. 46%), but fewer mono-pharmacotherapy patients 
used Medicaid (15% vs. 19%), and commercial insurance (22% vs. 27%) compared to 
combination pharmacotherapy patients. Overall, there was a statistically significant 
difference in insurance between mono- and combination pharmacotherapy group 
(p=0.001). More mono-pharmacotherapy patients lived in the West (15% vs. 12%) and 
Puerto Rico (6% vs. 3%), fewer of them lived in Midwest (17% vs. 20%) and Northeast 
(21% vs. 25%) compared with combination pharmacotherapy patients, and it was  
statistically significantly different (p=0.007). Fewer mono-pharmacotherapy patients had 
over seven co-morbidities compared with combination pharmacotherapy patients (19% vs. 
24%), and it was a statistically significantly different (p=0.038). In terms of the 





(625 vs.578) and shorter post-index enrollment days (819 vs. 836) than combination  
pharmacotherapy patients, but differences were not statistically significantly (pre-index: 
p=0.342; post-index p=0.404) (Table 3.4).  
 
3.1.3 Co-morbidities of DPN Patients 
 
3.1.3.1 Results Against Hypothesis 2: People Who Take Combination 
Pharmacotherapy Have More Co-morbidities than Patients Who Take 
Mono-pharmacotherapy 
 
Table 3.5 shows the clinical co-morbidities of DPN patients in 6-month pre-index, 
and Table 3.6 shows the co-morbidities in 1-year post-index. In both pre- and post-index, 
the most common co-morbidity for the DPN patients is cardiovascular disorders (pre-
index: 89.3%; post-index: 95.8%), and the second-most common one is musculoskeletal 
pain conditions (pre-index: 59.4%; post-index: 74.5%), diabetes-related conditions (pre-
index: 24.4%; post-index: 35.5%), mental disorders (pre-index: 17.1%; post-index: 
24.3%), sleep disorders (pre-index: 8.9%; post-index:14.6%). Overall, patients have 
higher percentage in each co-morbidity in post-index compared with pre-index, 
indicating patients have more co-morbidities after taking DPN medications.   
To compare patients with mono-pharmacotherapy and combination 
pharmacotherapy, there were fewer patients with mental disorders (pre-index: 17% vs. 
24%, p<0.001; post-index: 24% vs. 36%, p<0.001) and musculoskeletal pain conditions 
(pre-index: 59% vs. 66%, p=0.003; post-index: 74% vs. 86%, p<0.001) in mono-
pharmacotherapy group during study period. However, there were no statistically 
significantly differences in patients with cardiovascular disorders (pre-index: 0.070; post-















  (n=7145)   (n=421) 
Age(y), mean (standard deviation) 64.6±11.7 60.6±11.5 <0.001 
18-44 400 6% 39 9% <0.001 
45-65 3056 43% 227 54%   
>=65 3689 52% 155 37%   
Gender         0.111 
Male 3254 46% 175 42%   
Female 3891 54% 246 58%   
Insurance Plan Type         0.001 
Commercial 1559 22% 115 27%   
Medicaid 1069 15% 82 19%   
Medicare 3985 56% 194 46%   
Missing 522 7% 30 7%   
Region         0.007 
West 1056 15% 49 12%   
Midwest 1199 17% 85 20%   
Northeast 1477 21% 104 25%   
South 2795 39% 163 39%   
Puerto Rico 412 6% 12 3%   
Missing 206 3% 8 2%   
Numbers of Comorbidities           
With1-4 comorbidities 2343 33% 137 33% 0.038 
With5-7 comorbidities 3465 48% 185 44%   
With >7 comorbidities 1337 19% 99 24%   
Pre-index enrollment days (Median) 625 578 0.342 



























  (n=7145)   (n=421) 
Cardiovascular disorders 6395 90% 365 87% 0.070 
Congestive heart failure 1010 14% 64 15% 0.542 
Peripheral vascular disease 1622 23% 96 23% 0.961 
Cerebrovascular disease 817 11% 47 11% 0.865 
Coronary heart disease 1830 26% 105 25% 0.759 
Hypertension 5326 75% 296 70% 0.053 
Hyperlipidemia 4748 66% 264 63% 0.114 
Diabetes-related conditions 1752 25% 93 22% 0.259 
Retinopathy 848 12% 42 10% 0.242 
Nephropathy 1191 17% 64 15% 0.432 
Mental disorders 1191 17% 101 24% <0.001 
Depression 972 14% 87 21% <0.001 
Bipolar disorder 68 1% 6 1% 0.337 
Anxiety 345 5% 25 6% 0.305 
Sleep disorders 633 9% 38 9% 0.907 
Insomnia/sleep disorders 633 9% 38 9% 0.907 
Musculoskeletal pain conditions 4217 59% 279 66% 0.003 
Arthritis and other arthropathies 2061 29% 165 39% <0.001 
Rheumatoid arthritis 153 2% 9 2% 0.996 
Low back pain 1570 22% 126 30% <0.001 
Back and neck pain, other than low back pain 774 11% 57 14% 0.084 


























    (n=7145)   (n=421) 
Cardiovascular disorders 6853 96% 398 95% 0.169 
Congestive heart failure 1478 21% 88 21% 0.915 
Peripheral vascular disease 2329 33% 139 33% 0.858 
Cerebrovascular disease 1338 19% 83 20% 0.614 
Coronary heart disease 2507 35% 151 36% 0.745 
Hypertension 6134 86% 356 85% 0.462 
Hyperlipidemia 5706 80% 330 78% 0.464 
Diabetes-related conditions 2544 36% 141 33% 0.378 
Retinopathy 1319 18% 80 19% 0.781 
Nephropathy 1775 25% 97 23% 0.405 
Mental disorders 1684 24% 151 36% <0.001 
Depression 1390 19% 128 30% <0.001 
Bipolar disorder 81 1% 8 2% 0.156 
Anxiety 565 8% 45 11% 0.042 
Sleep disorders 1021 14% 87 21% <0.001 
Insomnia/sleep disorders 1021 14% 87 21% <0.001 
Musculoskeletal pain conditions 5270 74% 364 86% <0.001 
Arthritis and other arthropathies 3125 44% 233 55% <0.001 
Rheumatoid arthritis 248 3% 13 3% 0.676 
Low back pain 2296 32% 187 44% <0.001 
Back and neck pain, other than low 
back pain 
1295 18% 112 27% <0.001 










the study period. For sleep disorders, fewer patients in the mono-pharmacotherapy group 
had the disease in post-index (14% vs. 21%, p<0.001), but there was not a statistically 
significantly difference in pre-index (p=0.907) (Table 3.5, Table 3.6).  
Among specific co-morbidity, most differences are not statistically significantly 
different between patients with mono- and combination pharmacotherapy. However, 
there were fewer patients with depression (pre-index: 14% vs. 21%, p<0.001; post-index: 
24% vs. 36%, p<0.001), arthritis and other arthropathies (pre-index: 29% vs. 39%, 
p=0.003; post-index: 44% vs. 55%, p<0.001), and low back pain (pre-index: 22% vs. 
30%, p=0.003; post-index: 32% vs. 44%, p<0.001) in mono-pharmacotherapy group 
during study period. For back/ neck pain and rheumatism, fewer patients in the mono-
pharmacotherapy group had the disease in post-index, but there was no statistically 
significantly different in pre-index. Overall, patients with combination pharmacotherapy 
had more co-morbidities than patients with mono-pharmacotherapy (Table 3.5, 3.6). 
 
3.2 Treatment Patterns of DPN Patients 
3.2.1 Results Against Hypothesis 1: Patients Who Take Combination  
Pharmacotherapy Are Less Likely to Discontinue, Switch, or  
Add on Another Treatment than Patients Who  
Take Mono-pharmacotherapy 
 
Figure 3.2 shows that from 2006 to 2012, the percentages of the patients who use 
mono-pharmacotherapy and the patients who use combination pharmacotherapy have not 
changed. There are around 94% to 96% of the patients with mono-pharmacotherapy, and 
around 4% to 6% of the patients with combination pharmacotherapy. Table 3.7 shows the 
patient distribution in different DPN agents among different treatment groups during the 






Figure 3.2 Percentages of Mono- and Combination Pharmacotherapy from 2006-
2012 
 
than one agent, which means a single agent did not effectively treat those patients. There  
are 1,128 patients who use two agents, 165 patients who use three agents, 11 patients who 
use four agents, and one patient who uses five agents. Overall, it is more common for 
patients to use one agent through the study period. Among patients who use mono- 
pharmacotherapy, 2,420 of them are in the discontinued group (33.9%), 4,162 of them are 
in the nonswitch group (58.3%), 260 of them are in the switch group (3.6%), and 303 of 
them are in the add-on group (4.2%). Among patients who use combination 
pharmacotherapy, 199 of them are in the discontinued group (47.3%), 170 of them are in 
the nonswitch group (40.4%), 23 of them are in the switch group (5.5%), and 29 of them 
are in the add-on group (6.8%). Overall, combination pharmacotherapy patients have a 
lower proportion of nonswitch than mono-pharmacotherapy patients (40% vs. 58%), but 
having a higher percentage in discontinuation (47% vs. 34%), switch (5% vs. 4%) and 
add-on (7% vs. 4%).  
95% 94% 94% 94% 96% 95% 94% 




































Table 3.7 Patient Distribution in Different DPN Agents Among Different Treatment 
Groups During the Study Period 
 
Treatment Groups Number of Drugs used During Study Period 
One Two Three Four Five Total 
N % N % N % N % N % N % 
Mono-
Pharmacotherapy 
                        
  Discontinue 2099 34% 301 37% 20 27% 0 0% 0 0% 2420 34% 
  Non-Switch 4162 66% 0 0% 0 0% 0 0% 0 0% 4162 58% 
  Switch 0 0% 230 29% 30 41% 0 0% 0 0% 260 4% 
  Add-on 0 0% 272 34% 25 33% 6 100% 0 0% 303 4% 
Total 6261 100% 803 100% 75 100% 6 100% 0 100% 7145 100% 
Combination 
Pharmacotherapy 
                        
  Discontinue 0 0% 163 50% 35 38% 1 20% 0 0% 199 47% 
  Non-Switch 0 0% 161 50% 9 10% 0 0% 0 0% 170 40% 
  Switch 0 0% 0 0% 30 33% 2 40% 1 100% 23 5% 
  Add-on 0 0% 0 0% 27 30% 2 40% 0 0% 29 7% 
Total 0 0% 324 100% 91 100% 5 100% 1 100% 421 100% 
 
Table 3.8 shows that patients who take mono-pharmacotherapy discontinue in a 
mean of 74.4 days, which is shorter than the time of the patients who take combination 
pharmacotherapy (111.9 days), and patients who take combination pharmacotherapy are 
1.30 times as likely to discontinue as patients who take mono-pharmacotherapy (95% CI: 
1.31- 1.51, p<0.001) (Figure 3.3). Patients who take combination pharmacotherapy 
switch to another medication in a mean of 124.3 days, which is shorter than the patients 
who take mono-pharmacotherapy (143.4 days). However, there is no statistically 
significantly different between mono- and combination pharmacotherapy patients in time 
to add on (p=0.254) (Figure 3.4). Patients who take mono-pharmacotherapy add on 
another medication in a mean of 125.5 days, which is shorter than the patients who take 












Discontinue (N) 2420 (33.9 %) 199 (47.3 %) 
Days to discontinuation, mean 74.4 114.4 
Median 49 98 
Hazard Ratio Ref 1.30 
95% Confidence Interval Ref 1.13- 1.51 
P value Ref < 0.001 
Switch (N) 260 (3.6 %) 23 (5.5 %) 
Days to switching, mean 143.4 124.3 
Median 127.5 103 
Hazard Ratio Ref 1.28 
95% Confidence Interval Ref 0.84- 1.96 
P value Ref 0.254 
Add-on (N) 303 (4.2 %) 29 (6.9 %) 
Days to augmentation, mean 125.3 133.5 
Median 99 100 
Hazard Ratio Ref 1.42 
95% Confidence Interval Ref 0.97-2.09 










significantly difference between mono- and combination pharmacotherapy patients in 
time to add on (p=0.069) (Figure 3.5). 
 
3.2.2 Treatment Patterns in Mono-pharmacotherapy Group 
Most mono-pharmacotherapy patients started with gabapentin (n=3980, 55.7%), 
followed by opioids (n=936, 13.1%), pregabalin (n=920, 12.9%), TCAs (n=817, 11.4%), 
duloxetine (n=385, 5.4%), and lidocaine (n=107, 1.5%) for their index medicine. Patients 
who started with an opioid had the highest percentage to discontinue (51%), followed by 
patients who started with lidocaine (49%), gabapentin (33%), pregabalin (31%), TCAs 
(25%), duloxetine (25%). The numbers of discontinuations were statistically significantly 
different among the six index medicines (p=0.0001). Patients who started with pregabalin 
had the highest percentage of switching to another medication (7%), followed by patients 
who started with lidocaine (6%), TCAs (5%), gabapentin and duloxetine (3%), opioids 
(2%). The numbers of people switching were statistically significantly different among 
the six index medicines (p=0.0001). Patients who started with duloxetine had the highest 
percentage of adding on another medication (8%), followed by patients who started with 
TCAs (6%), opioids (5%), pregabalin and lidocaine (4%), gabapentin (3%). The numbers 
who added on were statistically significantly different among the six index medicines 
(p=0.0001). Patients who started with duloxetine also had the highest percentage of 
staying on the same treatment (68%), followed by patients who started with TCAs (64%), 
gabapentin (60%), pregabalin (58%), lidocaine (43%), opioids (42%). The numbers of 
nonswitching were statistically significantly different among the six index medicines 























Table 3.9 Patient Distribution in Index Medicine Among Different Mono-
pharmacotherapy Treatment Groups 
 











N % N % N % N % N 
Pregabalin 283 31% 536 58% 61 7% 40 4% 920 
Gabapentin 1319 33% 2403 60% 124 3% 134 3% 3980 
Duloxetine 82 21% 262 68% 12 3% 29 8% 385 
Opioids 476 51% 390 42% 19 2% 51 5% 936 
TCAs 208 25% 525 64% 38 5% 46 6% 817 
Lidocaine  52 49% 46 43% 6 6% 3 3% 107 
Total 2420 34% 4162 58% 260 4% 303 4% 7145 
Opioids: tramadol, oxycodone, morphine, oxymorphone, methadone, levorphanol, hydrocodone, 
hydromorphone; TCAs: amitriptyline, desipramine, nortriptyline 
 
Figure 3.6 shows from 2006 to 2012, more patients used gabapentin and opioids 
in 2012 than in 2006. Fewer patients used TCAs, pregabalin, and duloxetine in 2012 than 
in 2006; however, there was no difference in the usage of lidocaine from 2006 to 2012.  
Among patients who discontinued in the mono-pharmacotherapy, patients who 
were treated with opioids were 2.78 times as likely to discontinue as patients with TCAs 
(95% CI: 2.3-3.2, p<0.001), followed by lidocaine (HR: 2.49, 95% CI: 1.8- 3.4,  
p<0.001), gabapentin (HR: 1.34, 95% CI: 1.2-1.6, p<0.001), and pregabalin (HR: 1.25, 
95% CI: 1.0-1.5, p=0.016). Patients who started with an opioid had the shortest treatment 
before discontinuation, which was a mean of 47.3 days, and patients who started with  
duloxetine had the longest treatment before discontinuation, which was a mean of 91.5 
days (Table 3.10; Figure 3.7).  
Among patients who switched to another medication in the mono-
pharmacotherapy group, patients who were treated with pregabalin were 1.55 times as 












treated with gabapentin were 0.68 times as likely to switch as patients with TCAs (95% 
CI: 0.5-1.0, p=0.038), followed by opioids (HR: 0.5, 95%CI: 0.3-0.9, p=0.014). Patients 
who were treated with opioids took the longest time to switch to another medication, 
which was a mean of 170.3 days, and patients who were treated with lidocaine took the 
shortest time to switch to another medication, which was a mean of 93.2 days (Table 3.10; 
Figure 3.8). 
Among patients who added on to another medication in the mono-
pharmacotherapy group, patients in the gabapentin group were 0.59 times as likely to add 
on as patients with TCAs (95% CI: 0.4-0.8, p=0.002). Patients who began with 
duloxetine took the shortest time to add on another medicine, which was a mean of 102.2 
days, and patients who began with lidocaine took the longest time to add on another 









































Table 3.10 Switching, Add-on, and Discontinuation of Therapy of Index Medicine 
  
 Pregabalin Gabapentin Duloxetine Opioids TCAs Lidocaine  




























P value 0.016 <0.001 0.067 <0.001 Ref <0.001 
Switch (N) 61 123 12 19 38 6 


























P value 0.035 0.038 0.135 0.014 Ref 0.260 
Add-on (N) 40 134 29 51 46 3 


























P value 0.265 0.002 0.230 0.904 Ref 0.331 












































Overall, there were 260 patients who switched to another medication in the mono-
pharmacotherapy group. Figure 3.10 shows pregabalin patients mostly tend to switch to  
gabapentin (n=42, 68.9%), and gabapentin patients mostly tend to switch to pregabalin 
 (n=68, 54.8%). If gabapentin patients do not switch to pregabalin, they tend to switch to 
opioids (n=20, 16.1%). Patients tend to switch between pregabalin and gabapentin 
because pregabalin and gabapentin are all α2-δ subunit voltage-gated calcium channel 
antagonists; therefore, switching to the different medicine does not change the 
mechanism acted on the patients. However, the reasons of switching may be adverse 
effects or the cost difference between pregabalin and gabapentin (Figure 3.10).  
Duloxetine (n=5, 41.7%), opioids (n=11, 57.9%), TCAs (n=25, 65.8%), and 
lidocaine (n=4, 66.7%) patients tended to switch to gabapentin, that is to say, other than 
the patients who started with gabapentin, the rest of them tended to switch to gabapentin. 
If duloxetine patients did not switch to gabapentin, they tended to switch to opioids, 
pregabalin, or another two medications, (n=2, 16.7%) which were TCAs-pregabalin 
combination and opioids-gabapentin combination. If opioids and lidocaine patients did 
not switch to gabapentin, opioid patients tended to switch to TCAs (n=3, 15.8%), and 
lidocaine patients tended to switch to either TCAs or duloxetine- gabapentin combination 
(n=1, 16.7%). If TCAs patients did not switch to gabapentin, they tended to switch to 
pregabalin (n=8, 21%). If pregabalin patients did not switch to gabapentin, they tended to 
switch to antidepressants, which was either TCAs or duloxetine (n=6, 9.8%) (Figure 
3.10). 
There were 303 patients who had another medication added after the index 







 Opi: opioids; Dul: duloxetine; Gab: gabapentin; Pre: pregabalin; Lido: lidocaine 
 
Figure 3.10 Treatment Patterns of Mono-pharmacotherapy Patients (Switch) 
 
mostly tend to have duloxetine (n=21, 52.5%) added to their treatments. If pregabalin 
patients do not have duloxetine added, they tend to have gabapentin (n=7, 17.5%) added. 
It seems unreasonable to add a medicine with the same mechanism: gabapentin to 
pregabalin; however, physicians were possibly finding the right treatment from these two 
medications. Gabapentin patients mostly tend to have opioids (n=49, 36.6%) added to 
their treatments, and if they do not have opioids added, they tend to have antidepressants 
added, which was either duloxetine or TCAs (n=29, 21.6%). Duloxetine (n=13, 44.8%), 
opioids (n=31, 60.8%), and TCAs (n=31, 67.8%) patients tended to have gabapentin 
added to their treatments. If duloxetine, opioids, and TCA patients did not have 
gabapentin added, duloxetine patients tended to have pregabalin (n=7, 24.1%) added, 
opioids patients tended to have either TCAs or pregabalin (n=6, 11.8%) added, and TCAs 



























































 Opi: opioids; Dul: duloxetine; Gab: gabapentin; Pre: pregabalin; Lido: lidocaine 
 
Figure 3.11 Treatment Patterns of Mono-pharmacotherapy Patients (Add-on) 
 
3.2.3 Treatment Patterns in the Combination Pharmacotherapy Group 
There were 421 patients who initiated treatment with two or more drugs within 30 
days, representing 23 index combinations. These data are described in Table 3.11. The 
most common index combinations were opioids+ gabapentin (n=114, 27.1%), TCAs+ 
gabapentin (n=73, 17.3%), duloxetine+ gabapentin (n=36, 8.6%), opioids+ pregabalin 
(n=34, 8.1%), followed by the less common combinations: gabapentin+ pregabalin 
(n=31), TCAs+ opioids (n=20), gabapentin+ lidocaine (n=20), TCAs+ pregabalin (n=19), 
duloxetine+ pregabalin (n=18), opioids+ duloxetine (n=10), TCAs+ duloxetine (n=9), 
opioids+ lidocaine (n=9), pregabalin+ lidocaine (n=4), duloxetine+ lidocaine (n=1). 
There were 23 patients with 3 medicines on the index date, and they were TCAs+ 


























































Table 3.11 Classifications of the Combination Pharmacotherapy  
 









N % N % N % N % 
Opi +Gab 57 50% 46 40% 4 4% 7 6% 114 
TCA+Gab 34 47% 32 44% 4 5% 3 4% 73 
Dul+ Gab 12 33% 20 56% 2 6% 2 6% 36 
Opi+ Pre 15 44% 18 53% 0 0% 1 3% 34 
Gab+ Pre 24 77% 4 13% 1 3% 2 6% 31 
TCA+Opi 9 45% 6 30% 0 0% 5 25% 20 
TCA+ Pre 5 26% 11 58% 2 11% 1 5% 19 
Dul+ Pre 6 33% 8 44% 4 22% 0 0% 18 
Opi+ Dul 3 30% 3 30% 2 20% 2 20% 10 
TCA+Dul 3 33% 3 33% 1 11% 2 22% 9 
Any
*
 + Lido 18 53% 10 38% 2 6% 4 12% 34 
Two medicine total 186 51% 151 41% 22 6% 26 7% 364 
Three medicine 13 57% 9 39% 1 4% 0 0% 23 
* 
Opi+ Lido (n=9); Dul+ Lido (n=1); Gab+ Lido (n=20); Pre+ Lido (n=4) 
†
 Opi: opioids; Dul: duloxetine; Gab: gabapentin; Pre: pregabalin; Lido: lidocaine 
 
duloxetine+ pregabalin (n=4), TCAs+ duloxetine+ gabapentin (n=3), followed by the less  
common combinations: TCAs+ gabapentin+ pregabalin(n=2), TCAs+ duloxetine+ 
pregabalin (n=2), opioids + pregabalin+ lidocaine (n=1), TCAs+ gabapentin+ pregabalin 
(n=1), duloxetine+gabapentin+ lidocaine (n=1).  
Among patients with 2 medicines at the index, patients who started with 
gabapentin+ pregabalin group were most likely to discontinue (77%) during the study 
period. Patients who started with TCAs+ pregabalin had the highest nonswitch 
percentage (58%), and patients who started with duloxetine+ pregabalin were most likely 
to switch (22%) to another medication or medications. Patients who started with TCAs+ 
opioids were most likely to have another medication added (25%) (Table 3.11). 





and the peak was in 2011. Also, more patients used duloxetine+ gabapentin in 2012 than 
in 2006. However, fewer patients used TCAs+ gabapentin in 2012 than in 2006; fewer 
patients used opioids+ pregabalin in 2012 than in 2006, but the peak was in 2010. The 
usage of gabapentin+ pregabalin did not change, but the peak was in 2010 (Figure 3.12). 
Among patients who started with two medications, 22 of them had switched to 
another two medications after the index date, and most of them switched to another two 
medications evenly. Patients who started with duloxetine+ lidocaine only switched to 
opioid+ lidocaine (n=1), and patients who started with gabapentin+ pregabalin only  
switched to TCAs+ pregabalin (n=1). Patients who began with TCAs+ gabapentin tended 
to switch to TCAs+ pregabalin (n=3). Only one of them switched to another three  
medicines, which was opioids+ duloxetine+ gabapentin to TCAs+ opioids+ gabapentin 























































 Opi: opioids; Dul: duloxetine; Gab: gabapentin; Pre: pregabalin; Lido: lidocaine 
 




Among patients who started with two medications, 29 of them had another 
medication added after the index date. Patients who started with TCAs+ gabapentin/ 
pregabalin (n=4) and patients who started with duloxetine+ gabapentin (n=2) only had 
opioids added. Patients who began with opioids+ gabapentin/ pregabalin (n=3) and 
patients who began with gabapentin+ pregabalin (n=2) tended to have duloxetine (n=2) 
added. Patients who started with TCAs+ opioids tended to have gabapentin (n=3) added. 



















































3.3 Predictors of Combination Pharmacotherapy in DPN Patients 
 
3.3.1 Results Against Hypothesis 3: Demographics and Clinical 
Characteristics Will Affect the Likelihood of Receiving 
Combination Pharmacotherapy 
 
Age, gender, insurance plan, region, and the numbers of co-morbidities were  
considered as predictors of receiving combination pharmacotherapy; however, there were 
no statistically significant differences in regions and insurance plan. Patients who were 
older than 65 compared to age 18- 44 (OR=0.44, 95% CI: 0.29- 0.66, p<0.001) were less 
likely to start with combination pharmacotherapy. Patients who were female compared to 
male (OR=1.25, 95% CI: 1.03- 1.55, p=0.003), with over seven co-morbidities compared 
to with one to four co-morbidities (OR=1.43, 95% CI: 1.09- 1.87, P=0.011), were more 











































Table 3.12 Characteristics Associated with Combination Pharmacotherapy 
(demographics) 
 
 Odds Ratio 95% CI P value 
Age    
18-44 Ref Ref Ref 
45-65 0.75 0.52-1.08 0.128 
>=65 0.44 0.29-0.66 0.000 
Gender    
Male Ref Ref Ref 
Female 1.26 1.03-1.55 0.024 
Insurance Plan Type    
Commercial Ref Ref Ref 
Medicaid 1.04 0.74-1.45 0.833 
Medicare 0.98 0.72-1.32 0.878 
Self- Insured 1.29 0.16-10.19 0.809 
Missing 0.89 0.58-1.37 0.591 
Region    
West Ref Ref Ref 
Midwest 1.44 0.98-2.11 0.061 
Northeast 1.39 0.98-1.99 0.065 
South 1.35 0.97-1.89 0.078 
Puerto Rico 0.74 0.39-1.42 0.374 
Missing 0.97 0.45-2.08 0.930 
Numbers of Comorbidities    
With 1-4 comorbidities Ref Ref Ref 
With 5-7 comorbidities 0.97 0.77-1.22 0.793 




Five disorders and conditions were considered as predictors of receiving 
combination pharmacotherapy: cardiovascular disorders, diabetes-related condition, 
mental disorders, sleep disorders, and musculoskeletal pain conditions. Patients who had 
mental disorders were more likely to start with combination pharmacotherapy than those  
without (OR=1.56, 95% CI: 1.24- 1.97, p< 0.001), and had musculoskeletal pain  





patients with cardiovascular disorders were less likely to start with combination 
pharmacotherapy than those without (OR= 0.73, 95% CI: 0.54-0.98, p=0.037) (Table 
3.13).  
Among specific co-morbidity as predictors of receiving combination 
pharmacotherapy, only three of the 17 co-morbidities in our study had statistically 
significant differences. Patients who had hypertension compared to those without 
(OR=0.79, 95% CI: 0.63-0.99, p=0.045) were less likely to start with combination 
pharmacotherapy. However, patients who had depression (OR=1.59, 95% CI: 1.23-2.05, 
p<0.001), and arthritis (OR=1.54, 95% CI: 1.24-1.95, p<0.001) compared to those 
without were more likely to start with combination pharmacotherapy (Table 3.14).  
 
3.4 Healthcare Costs of DPN Patients 
3.4.1 Results Against Hypothesis 4: Patients Who Take Combination  
Pharmacotherapy Have Lower Medical Costs than Patients  
Who Take Mono-pharmacotherapy 
 
The average total mean cost was $5,874 in the 6-month pre-index, and among all 
the treatment groups, patients who discontinued in the combination pharmacotherapy 
group had the highest 6-month pre-index mean cost: $8,527; patients who added on 
another medication in the combination pharmacotherapy group had the lowest pre-index 
mean cost: $2,280. The same as the pre-index, patients in the combination 
pharmacotherapy group who switched to another two medications had the highest 1-year 
post-index mean cost: $25,423; patients who added on another medication in the 
combination pharmacotherapy group had the lowest post-index mean cost: $8,514. The 





Table 3.13 Characteristics Associated with Combination Pharmacotherapy (co-
morbidities)  
 
 Odds Ratio 95% CI P value 
Cardiovascular disorders 0.73 0.54-0.98 0.037 
Diabetes-related condition 0.89 0.70-1.12 0.319 
Mental disorders 1.56 1.24-1.97 0.000 
Sleep disorders 0.95 0.67-1.34 0.750 




Table 3.14 Characteristics Associated with Combination Pharmacotherapy (specific co-
morbidities) 
 
  Odds Ratio 95% CI P value 
Cardiovascular disorders       
Congestive heart failure 1.14 0.84-1.54 0.407 
Peripheral vascular disease 1.02 0.80-1.30 0.879 
Cerebrovascular disease 0.92 0.67-1.28 0.631 
Coronary heart disease 0.96 0.75-1.24 0.755 
Hypertension 0.79 0.63-0.99 0.045 
Hyperlipidemia 0.89 0.72-1.10 0.282 
Diabetes-related condition      
Retinopathy 0.86 0.61-1.19 0.360 
Nephropathy 0.91 0.68-1.22 0.526 
Mental disorders      
Depression 1.59 1.23-2.05 <0.001 
Bipolar disorder 1.26 0.54-2.94 0.597 
Anxiety 1.04 0.67-1.61 0.861 
Sleep disorders      
Insomnia/sleep disorders 0.93 0.65-1.31 0.669 
Musculoskeletal pain conditions      
Arthritis and other arthropathies 1.54 1.24-1.92 <0.001 
Rheumatoid arthritis 0.87 0.44-1.72 0.687 
Low back pain 1.39 1.10-1.75 0.005 
Back and neck pain, other than low back pain 1.03 0.76-1.41 0.832 







The pre-index total costs of the mono-pharmacotherapy group were not 
statistically significantly lower than the combination pharmacotherapy group ($5,743 vs. 
$7,936, p=0.05). The post-index total costs of the mono-pharmacotherapy group were 
statistically significantly lower than the combination pharmacotherapy group ($12,950 
vs. $15,643, p=0.02) (Table 3.15).  
The cost difference is total mean post-index cost minus the total mean pre-index 
cost; in order to have the consistent time frame for pre- and post-index, the mean cost 
only included 6-month post-index cost. There was no statistically significant difference 
between mono-pharmacotherapy and combination pharmacotherapy group in the cost 
difference ($818 vs. $1,425, p=0.63) (Figure 3.15).The lowest cost difference was 
patients in combination pharmacotherapy group who stayed on the same treatment  
($ -1,901), and the highest cost difference was patients in combination pharmacotherapy 
group who switched to another two medications ($ 9,499) (Figure 3.16).  
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4.1 Summary of Study Findings 
Based on the IOM report: Relieving Pain in America, the US spends at least $560 
to $635 billion annually on chronic pain.
77
 DPN patients are included in chronic pain 
patients, whose pain can cause them not go to work when symptoms are present, lose 
sleep, or require caregivers to take care of their daily life. According to the literature, 
DPN patients are under treated, and for those who are treated, many of them cannot 
control their pain well even when they take their medicine with good adherence. Since 
many DPN patients are not being effectively treated, it leads to additional office/ ER 
visits and higher healthcare costs. In order to find the optimal treatment for newly-treated 
DPN patients, the current study is designed to quantify DPN treatment patterns, 
determine the types of combination pharmacotherapy, describe the co-morbidities, 
determine the predictors of the patients who received combination pharmacotherapy, and 
compare healthcare costs between mono-pharmacotherapy and combination 
pharmacotherapy. 
The results showed the proportion of mono-pharmacotherapy (94.4%) was much 
higher than combination pharmacotherapy (5.6%). The percentage of mono- 





compared with literature, which may be related to the majority of the study population 
being newly-treated patients. Gore et al. reported that 52.2% of DPN patients took at least 
two prescription medications,
22
 but the patients in the study had used pain medications an 
average of 5.4 years, which was different from this cohort where everyone was newly-
treated. Another reason for the difference is the definition of the combination 
pharmacotherapy. Hall et al. investigated newly-treated patients and reported that 16.9 % 
of DPN patients used at least two medications.
25
 However, the days of the prescription 
filled and the overlap periods of two medications were not described, and it is possible 
that they do not have any overlap periods or have a really short one. Even though a 10-
day overlap of two prescriptions can be considered as using two medications, it is more 
for short-term rescue, which is not the purpose of this study.  The purpose of this study is 
to define the optimal combination pharmacotherapy for newly-treated DPN patients. On 
the other hand, each medication had at least a 60-day prescription fill and a 60-day 
overlap in this cohort. The last reason for lower combination pharmacotherapy in this 
cohort is that only DPN guideline-suggested medications were investigated, whereas in 
the literature both OTCs and NSAIDs were included. Even though the proportions of 
patients who take combination pharmacotherapy seem small in this study, the strict 
definitions, newly-treated patients and only including guideline-suggested medications 
might be the reason for the number differences. 
This study showed that once patients are on combination pharmacotherapy they 
are more likely to discontinue from index medications. The addition of a new medication 
or switching is no different for either group, so it seems that adding on another medicine 





pharmacotherapy or they were already on combination pharmacotherapy. In other words, 
whether the DPN patients started with mono- or combination pharmacotherapy, the first 
treatment is ineffective, and both mono- and combination pharmacotherapy patients are 
likely to fail. However, this conclusion is from the treatment patterns, not the pain scales, 
which is more standard to define treatment efficacy. Overall, the study disproves the 
hypothesis that patients who take combination pharmacotherapy for DPN are less likely 
to discontinue, switch, or add on therapy than patients who take mono-pharmacotherapy. 
This may be related a higher priority control blood pressures and blood sugars, and thus 
the symptoms of pain seem less important; therefore, patients who start with combination 
pharmacotherapy tended to discontinue from two medications to one medication.  





 and EFNS guidelines.
36
 Gabapentin was the most 
commonly prescribed medication as the index medicine in this cohort (55.7%), followed 
by opioids (13.1%), pregabalin (12.9%), TCAs (11.4%), duloxetine (5.4%), and lidocaine 
patch (1.5%). Even though gabapentin is not an FDA approved medication for DPN, it is 
the most commonly prescribed medicine in this cohort.
109
 The same results were also 
shown in the Chen et al. study when compared with duloxetine, TCAs, venlafaxine, 
pregabalin, and opioids, gabapentin is also prescribed most commonly.
97
 Opioids are not 
the first-line treatment in any of the DPN guidelines, but they are the second most 
commonly prescribed medication in this cohort. Physicians might prescribe them as a 
rescue medicine. In contrast, duloxetine is not being prescribed commonly in our study, 
which is aligned with UK cohort study that duloxetine and venlafaxine were prescribed in 
fewer than 2 % of DPN patients.
25





(17.6%), and duloxetine+ gabapentin (8.6%) are the most common combination groups in 
our study; noticeably, all the top three groups included gabapentin. Since this is the first 
observational study to investigate combination pharmacotherapy in DPN patients, there is 
no literature to prove or disapprove this result.   
Patients who started with duloxetine had the highest nonswitch percentages (68%), 
and Zhao et al. also showed duloxetine had better adherence compared with pregabalin.
98
 
Patients who started with TCAs-pregabalin combination had the highest nonswitch 
percentage (58%) compared with other combinations. Among patients with two 
medicines on the index date, patients who started with pregabalin and gabapentin were 
most likely to discontinue (77%). It makes sense that patients who start with gabapentin 
and pregabalin have the highest discontinue percentage, for physicians might prescribe 
both of them at first, and then discontinue one of the medications after, since pregabalin 
and gabapentin have the same mechanism or could be step therapy for using gabapentin 
first then pregabalin. Among all the medication, opioids discontinued in the shortest time 
(Median: 30 days), and had the highest discontinuations than other medications (51%). It 
demonstrates that opioids cannot be used in the long-term due to adverse effects, and the 
concerns about patient addiction. Even though it is recommended in guidelines to use 
gabapentin and opioids after the first-line treatment failure, 
39
 physicians should prescribe 
them with caution for opioids might increase risk of serious harms that appear to be dose-
dependent. Compared to patients who started with opioids, lidocaine, gabapentin, and 
pregabalin, patients who started TCAs are statistically significantly less likely to 
discontinue, which is similar to the recommendations in the review conducted by Dr. 







The recommended next steps after first-line treatment are suggested from 
guidelines as follows: change to another first-line agent; change to second-line agent; or 
add a different first- or second-line agent.
35
 However, in this cohort patients who either 
switched or added on after the initial treatment were only in a small proportion in the 
mono-pharmacotherapy group, which is 4%. Patients who started with pregabalin mono-
pharmacotherapy had the highest switch proportion than other medications (7%), and 
patients who started with duloxetine and pregabalin were most likely to switch (22%) 
compared to other combinations. Other than changing to another first-line agent, the 
guideline also suggests adding a different first- or second agent. In this study patients 
who started with duloxetine had the highest proportions to add on another medication 
(8%), and for patients in the combination pharmacotherapy group, 25% of patients who 
started with TCAs and opioids added on another medication. Overall, most patients in the 
mono-pharmacotherapy group tended to add on gabapentin, which is aligned with what 
the guidelines suggest: TEPDN guideline recommends to use gabapentin and opioid,
39
 




 Treatment patterns of mono- and combination pharmacotherapy show that 
physicians tend to prescribe mono-pharmacotherapy first, that gabapentin is the most 
commonly prescribed medicine, the most common medicine to be switched to and to be 
added on, and all the top three combination groups included gabapentin. The results are 
surprising, since pregabalin has better pharmacokinetics, only needs to be taken twice 
daily, and with not much cost difference. Furthermore, even though patients who used 





fewer physicians prescribed them as first-line treatment. Future study could explore the 
reasons for physicians’ prescribing patterns in DPN patients. The study also reported that 
there is a statistically significantly difference in regions between mono- and combination 
pharmacotherapy group, which is aligned with the McDonald et al. study:
118
 they 
concluded that there are residual geographic variation in opioid prescribing. There is also 
a statistically significantly difference in insurance between mono- and combination 
pharmacotherapy group.  Guo et al. used Medical Expenditures Panel Survey (MEPS) to 
examine the role of insurance type in the selection of antihypertensives, and it also 
showed the statistically significantly difference in insurance among different treatments. 
Patients with health maintenance organization insurance were less likely than fee for 
service (FFS) patients to follow the US Joint National Committee (JNC) guidelines; 
patients with all other public insurance and no insurance were not statistically different 
from the FFS group of following JNC guidelines
119
 
 Patients who took combination pharmacotherapy had more co-morbidities than 
patients who took mono-pharmacotherapy, and they had more mental disorders and 
musculoskeletal pain condition in all study periods, and more sleep disorders after they 
took DPN medication. This demonstrates the hypothesis is true that patients who take 
combination pharmacotherapy have more co-morbidity. The study also proved that 
demographics and clinical characteristics will affect the likelihood of receiving 
combination pharmacotherapy. Patients who were female compared to male, who had 
more than seven co-morbidities compared to less than five co-morbidities, who had 
depression, arthritis compared to those without, were more likely to start with 





age 18 to 44, who had hypertension compared to other co-morbidities, were less likely to 
start with combination pharmacotherapy. Since this is the first observational study for 
comparing combination and mono-pharmacotherapy in newly-treated DPN patients, there 
is no available literature to confirm these results. However, Manteuffel et al. evaluated 
the differences between women and men in medication use reported that women were 
prescribed more medications than men,
120
 which can possibly lead to our results that 
females are more likely to start with combination pharmacotherapy. Bluher et al. used a 
questionnaire to evaluate the impact of pill burden found patients who were older than 65 
years old took more medications than those who were younger,
121
 which may explain 
why our older patients would be less likely to take combination pharmacotherapy. 
Because the pill burden is higher in the elderly, to prescribe two medications initially for 
their pain symptoms would be improbable. 
The annual mean cost is $13,111 in post-index, which is much lower than in the 
literature: $30,000 from either Pharmetrics 
21, 93
 or MarketScan database.
94, 97, 101
 The 
demographic distribution and co-morbidities were not much different between our 
cohorts and previous literature. The reason for the big difference in annual healthcare 
costs might be due to only 30% of the cohort having cost data, compared to MarketScan 
and Pharmatrics which have almost 100% cost data. Even though cost is only calculated 
for patients who have cost data, the reasons healthcare costs were still lower might be due 
to the missing data. 
In the prior 6 months to starting DPN medication, patients who started with 
combination pharmacotherapy and then added on another medication had the lowest pre-





the more likely the patients who start with combination pharmacotherapy will add on 
another medication. The reason will be the same as older patients being less likely to take 
combination pharmacotherapy initially. Since the older patients have more pill burden, 
patients who have less pill burden are more likely to start with combination 
pharmacotherapy and to add on another medication later. In both pre- and post-index, 
patients who discontinue combination pharmacotherapy had the highest cost, which 
shows that poor adherence leads to high healthcare costs, and it follows the Wu et al. 
study which reported that the lowest duloxetine compliance group had the highest 
healthcare costs.
104
 Both in mono- and combination pharmacotherapy group, patients who 
stayed on the treatment had the lowest cost difference from post-index to pre-index, 
implying better adherence has the lowest costs. 
The pre-index total costs of patients who started with mono-pharmacotherapy 
were not statistically significantly lower than patients who started with combination 
pharmacotherapy, but it was statistically significantly lower than patients who started 
with combination pharmacotherapy in the post-index, which is disproving the hypothesis 
that patients who take combination pharmacotherapy will have lower healthcare cost. 
However, patients who started with combination pharmacotherapy had more co-
morbidities, and the literature showed that the higher numbers of the co-morbidities will 
lead to the higher costs. Therefore, patients who start with combination pharmacotherapy 
group will have higher costs. Even though it is disproving the hypothesis, the cost 
difference showed there was no statistically significant difference ($818 vs. $1,425, 






4.2 Discussion and Implication of Study Findings 
 This is the first published observational study to investigate combination 
pharmacotherapy usage in DPN patients. Even though the sample size of the combination 
pharmacotherapy patients is small (n=421), the descriptive results are still important.  
Based on the mechanism approach and the multiple symptoms of each DPN patient, 
combination pharmacotherapy might be the only effective way to treat DPN patients.
67
 
The results showed that patients who were older and had hypertension would be less 
likely to receive combination pharmacotherapy. This may because the older patients have 
the higher likelihood of having drug-drug interaction,
122
 and hypertensive patients need to 
take antihypertension medications at the same time. The fact that DPN patients frequently 
take multiple medications may also cause fewer physicians to prescribe combination 
pharmacotherapy for them. Also, it is common for physicians to prescribe initial 
treatment first, then add on another medicine later. In our cohort, the combination 
pharmacotherapy is defined as having two or more medications within first 30 days. 
Since the result has shown taking combination pharmacotherapy would not cost more 
money if considering the pre-index cost, it is recommended to add on another medication 
sooner than 30 days if there is inadequate response. Moreover, as a result of increasingly 
used and implementation of patient report outcome into trials and healthcare strategy,
123
 
it is important to understand whether patients prefer to treat their pain symptoms rather 
than blood pressures or blood sugars, and will the physicians be willing to treat a 
patient’s pain symptoms first if the patient has this preference?  
 Patients who were female, with more than seven co-morbidities, and had 





research could investigate whether initial combination pharmacotherapy be more 
effective in patients with depression or arthritis. If the hypothesis is true, then the 
physicians should prescribe combination pharmacotherapy to them initially.  
 There were only 58% of the patients who had stayed on the same treatment in 
mono-pharmacotherapy group, and there were only 40% of the patients who stayed on 
the same treatment in combination pharmacotherapy group. It is suggested that the DPN 
medications remain unsuccessful to DPN patients based on the treatment patterns. More 
comprehensive pain registries need to be developed to create more cohort studies and 
find a better analgesic or a better combination regimen for DPN patients, and in the 
meantime patients need to learn a better coping strategy for their pain conditions.  
 The literature has described that multiple co-morbidities is normal for DPN 
patients, which may make our co-morbidities results insignificant. However, comparing 
the co-morbidities between patients with combination and mono-pharmacotherapy has 
never been done. Patients who take combination pharmacotherapy had more co-
morbidities, and patients with mental disorders and other pain conditions were more 
likely to take combination pharmacotherapy. However, how different co-morbidities lead 
to different combination regimens, and which regimens are the most effective in terms of 
demographic and clinical characteristics should be explored in future research. Because 
in this cohort all the combination regimens were combined to combination 
pharmacotherapy, it is clear that each regimen is different; therefore, it is worthwhile to 
investigate the characteristic differences between regimens, and their safety and efficacy.  
 The study also found out patients who stay on the same treatment would have the 





concluded there are the discordances between evidence and public policy in atrial 
fibrillation patients, and the reasons are variance with national guidelines and the funding 
restrictions for evidence-based therapies.
124
 The same problems exist in DPN patients; 
there are no standardized guidelines for DPN,
41
 there is step therapy and prior 
authorization to restrict the usages of evidence-based therapies. Therefore, it is hard for 
providers to adhere to clinical guidelines. Waddimba et al. reported providers who had 
the support from peers and who perceived financial rewards for quality care would have 
better adherence to the guidelines.
125
 Pozniak et al. presented physicians do not have 
enough reimbursements for their diabetic care.
105
 Future implications would be to provide 
more reimbursements for physicians, having a consistent clinical guideline to help policy 
makers, and considering medication costs for reimbursing DPN medications.  
 
4.3 Limitations, Conclusions, and Recommendations for Future Research 
This study only included newly-treated patients and having only one year follow-
up, which may not be the best study design for a chronic disease. However, in order to 
thoroughly compare mono-pharmacotherapy with combination pharmacotherapy in DPN 
patients, it is necessary to stratify them on their first DPN prescription. The hypothesis 
therefore can be tested: Do patients who start with combination pharmacotherapy more 
easily discontinue, add on, or switch than patients who start with mono-pharmacotherapy? 
How is the time to discontinue, add on, or switch different from mono-pharmacotherapy 
and combination pharmacotherapy? 
Classification bias is possible given the way patients were classified. Four 





and add-on. It was required only that medication added on another medication for 60 
days, not for the entire follow-up. The same requirements were followed with the switch 
group: the switch medicine might only be switched for 60 days. Even if it switched back 
to the original medicine afterwards, this still counted a patient as part of the switch group. 
Additionally, since only the first sequence of medication had been captured, the patient 
might switch to another medication for 60 days then add on to the same medication for 
180 days; however, as a group it was still counted as the switch. Even though in reality 
there are flaws in this categorization, this is the most detailed and precise methodology 
described in the literature. Each group is mutually exclusive, and no patient has been 
excluded if the patient has at least a 60-day prescription filled in any DPN medication. 
The patterns have been described, including the index medicine, the second medicine, 
and the time to the first medication change. The definition of the switch or the add-on 
group might be different from clinical practice, but both combination and mono-
pharmacotherapy patients were included.  For better comprehensive overview of the DPN 
treatment patterns, future study should also include multiple treatment sequences and 
have more strict requirements for the switch and the add-on group. 
Not all the guidelines suggested DPN medications are included in this study. 
NSAIDs or other over-the-counter (OTC) medications are not included. Patients might 
take other analgesics at the same time, but they are not being considered for combinations. 
However, the purpose of this study is to see the characteristics and optimal combination 
pharmacotherapy for newly-treated patients with DPN. OTC medications or other 
analgesics are not effective in DPN patients; therefore, it is not considered. In this study, 





and hydromorphone were counted as a single opioids category. That is to say, if patients 
used any of these opioids during study time, it was counted as continue, even with change 
to different kinds of opioids in between. The same issue is seen with TCAs; amitriptyline, 
desipramine, and notriptyline are all counted as TCAs. Future research may categorize 
opioids into immediate-release opioids and long-act opioids. TCAs could be separated 
into secondary amine and tertiary amine. 
 The parameters included in this study are insurance type, region, age, sex, and co-
morbidities, which are not comprehensive. Other parameters that would be worth 
investigating are the adherence, severity of diabetes, socioeconomic characteristics, 
provider characteristics, and medication history. Those parameters all have impact on the 
treatment choices, and the treatment patterns. To include them would help to categorize 
DPN patients more specifically, and to determine the predictors of the different treatment 
groups more precisely. Admittedly, a future study could investigate how those 
demographic and clinical characteristics affect each combination regimen, whereas this 
study only investigated between mono- or combination pharmacotherapy groups. 
The excluded patient numbers for each inclusion criterion are captured in the 
flowchart; however, many patients are missing cost data. Since Inovalon is a healthcare 
technology company, it does not require clients to provide cost data originally. 
Imputation might be a strategy; however, due to the massive amounts of the missing data 
and because the overall cohort patient characteristics are different from the with-cost 
cohort, it was not considered appropriate. Therefore, further research should consider the 
limitations of the cost data in Inovalon, and the validation of the database is encouraged 





Overall, patients who were older than 65 and those with hypertension were less 
likely to start with combination pharmacotherapy. Female patients, with more than seven 
co-morbidities, and who had depression or arthritis were more likely to start with 
combination pharmacotherapy. Patients who take combination pharmacotherapy are more 
likely to discontinue, having more co-morbidities, and more healthcare costs than patients 
who take mono-pharmacotherapy.  In order to offer better treatments to DPN patients, 
future study should look at each combination regimen, and tailor them to different patient 
characteristics. Because all first-line medications have similar efficacy, it is encouraged 
to consider cost for the treatment decision; therefore, gabapentin and TCAs will be the 
recommended medications. Because taking combination pharmacotherapy would not cost 
more money if considering the pre-index costs, it is recommended to add on another 
medication within 30 days. The policy maker can reimburse either gabapentin+ opioid or 
TCA+ gabapentin if condition is allowed. In conclusion, newly-treated DPN patients 
should add on another medication after initiating therapy sooner than 30 days when 







• Index date: the first prescription filled for DPN drug during the identification period.  
• Index Medicine: Medicine used on the index date, including following: TCAs, 
Opioids, Duloxetine, Gabapentin, Pregabalin, any route Lidocaine, and any of the 
combinations.  
• Mono-pharmacotherapy: Patients who take only one DPN medicine on the index date. 
Those receiving mono-pharmacotherapy with duloxetine or pregabalin or gabapentin 
or amitriptyline or desipramine or notriptyline or tramadol or oxycodone or morphine, 
or any route lidocaine. 
• Combination pharmacotherapy: Patients who are on two or more agents within 30 
days after initiation of therapy with a single agent. Those receiving multiple 
combination therapy with gabapentin+opioids, gabapentin+notriptyline or any other 
combinations for listed medication. The multiple combination therapy group would 
be patients who are on two or more agents within 30 days after initiation of therapy 
with a single agent.  
• Treatment groups: discontinue, nonswitch, switch, and add-on 
o Discontinue group: Patients who have a gap ≥ 60 days during study period 
will be defined as a discontinue group. If patients switched or added on 





o discontinue group.  
o Nonswitch group: Patients without any ≥ 60-day gap continued to have the 
same index medicine for at least 60 days, and did not have any medicine 
added on in following study period. 
o Switch group: Patients without any ≥ 60-day gap switched to another 
medicine, and the second medicine was taken for at least 60 days. Patients 
might switch from one medicine to two classes of medicine, or from two 
classes of medicine to one medicine, or switch from one to another one, two to 
another two. 
o Add-on group: Patients without any ≥ 60-day gap added on another medicine, 
and the index medicine and add-on medicine needed to be overlapped at least 
60 days. 
• The date of discontinuation: The end date (fill date + days supply) of the last 
prescription prior to discontinuation was designated.  
• Days to discontinuation were calculated as the number of days from the fill date of 
the index prescription to the end date of the last prescription prior to discontinuation. 
• Days to therapy switching were calculated as the number of days from the fill date of 
the index medicine to the fill date of the first prescription for the switched therapy.  
• Days to therapy augmentation were calculated as the number of days from the fill 







A.2 Comparison Between Overall and With-cost Data 
There were 2,478 patients having cost information before and after index-date. 
There were more combination pharmacotherapy patients in with-cost than the overall 
group (6.1% vs. 5.6%). Among mono-pharmacotherapy group, there were more patients 
who discontinued in with-cost group than overall group (35.9% vs. 33.9%). There were 
fewer patients who stay on in with-cost than overall group (53.6% vs. 58.3%) and fewer 
patients who added on another medication (3.7% vs. 4.2%). Among combination 
pharmacotherapy group, there were more patients who discontinued in with-cost group 
than overall group (49.3% vs. 47.3%) and more patients who stayed-on (42.7% vs. 
40.4%). There were fewer patients who switched to another medication in with-cost than 
overall group (3.3% vs. 5.5%) and fewer patients who added on to another medication 
(4.7% vs. 6.9%) (Table A.1). 
 
 






N % N % 
Mono-Pharmacotherapy 7145 94.4% 2328 93.9% 
Discontinue 2420 33.9% 836 35.9% 
Non-Switch 4162 58.3% 1327 53.6% 
Switch 260 3.6% 80 3.4% 
Add-on 303 4.2% 85 3.7% 
Multiple Combination 421 5.6% 150 6.1% 
Discontinue 199 47.3% 74 49.3% 
Non-Switch 170 40.4% 64 42.7% 
Switch 23 5.5% 5 3.3% 


















  (n=2357)   (n=150) 
Age(y), mean 64.4±11.7 60.0±11.7 <0.001 
 (standard deviation)  
18-44 130 6% 16 11% <0.001 
45-65 1022 43% 82 55%   
>=65 1209 51% 52 35%   
Gender         0.370  
Male 1046 44% 72 48%  
Female 1315 56% 78 52%   
Insurance Plan Type         0.096  
Commercial 436 18% 37 25%  
Medicaid 560 24% 43 29%   
Medicare 1346 57% 69 46%   
Self- Insured 11 0% 1 1%   
Missing 8 0% 0 0%   
Region         0.111  
West 264 11% 13 9%  
Midwest 210 9% 18 12%   
Northeast 759 32% 52 35%   
South 883 37% 61 41%   
Puerto Rico 227 10% 6 4%   
Missing 18 1% 0 0%   
Numbers of Comorbidities           
With1-4 comorbidities 694 29% 39 26% 0.629 
With5-7 comorbidities 1170 50% 76 51%   
With >7 comorbidities 497 21% 35 23%   
Pre-index enrollment days (Median) 673 723 0.641   

























    (n=2357) 
   
(n=150) 
Cardiovascular disorders 2164 92% 136 91% 0.621 
Congestive heart failure 338 14% 23 15% 0.737 
Peripheral vascular disease 528 22% 31 21% 0.621 
Cerebrovascular disease 305 13% 13 9% 0.127 
Coronary heart disease 618 26% 32 21% 0.185 
Hypertension 1839 78% 118 79% 0.853 
Hyperlipidemia 1615 69% 102 68% 0.894 
Diabetes-related condition 595 25% 36 24% 0.734 
Retinopathy 277 12% 15 10% 0.517 
Nephropathy 404 17% 25 17% 0.881 
Mental disorders 398 17% 35 23% 0.043 
Depression 324 14% 27 18% 0.145 
Bipolar disorder 24 1% 2 1% 0.712 
Anxiety 113 5% 12 8% 0.080 
Sleep disorders          
Insomnia/sleep disorders 223 9% 14 9% 0.959 
Musculoskeletal pain conditions 1479 63% 104 69% 0.105 
Arthritis and other arthropathies 753 32% 58 39% 0.088 
Rheumatoid arthritis 56 2% 2 1% 0.410 
Low back pain 560 24% 48 32% 0.022 
Back and neck pain, other than low back pain 274 12% 27 18% 0.020 





























  (n=2357)   (n=150) 
Cardiovascular disorders 2275 97% 143 95% 0.446 
Congestive heart failure 486 21% 29 19% 0.705 
Peripheral vascular disease 783 33% 43 29% 0.250 
Cerebrovascular disease 455 19% 28 19% 0.848 
Coronary heart disease 827 35% 41 27% 0.053 
Hypertension 2044 87% 130 87% 0.985 
Hyperlipidemia 1866 79% 122 81% 0.526 
Diabetes-related condition 839 36% 44 29% 0.119 
Retinopathy 433 18% 28 19% 0.928 
Nephropathy 581 25% 32 21% 0.359 
Mental disorders 553 23% 42 28% 0.205 
Depression 463 20% 34 23% 0.368 
Bipolar disorder 32 1% 4 3% 0.191 
Anxiety 167 7% 11 7% 0.909 
Sleep disorders           
Insomnia/sleep disorders 330 14% 31 21% 0.024 
Musculoskeletal pain conditions 1780 76% 129 86% 0.003 
Arthritis and other arthropathies 1050 45% 92 61% <0.001 
Rheumatoid arthritis 88 4% 0 0% 0.016 
Low back pain 778 33% 68 45% 0.002 
Back and neck pain, other than low back pain 463 20% 46 31% 0.001 













Table A.5 Characteristics Associated with Combination Pharmacotherapy 
(demographics)- With Cost 
 
 Odds Ratio 95% CI P value 
Age    
18-44 Ref Ref Ref 
45-65 0.62 0.34-1.11 0.107 
>=65 0.34 0.17-0.67 0.002 
Gender    
Male Ref Ref Ref 
Female 0.92 0.65-1.28 0.612 
Insurance Plan Type    
Commercial Ref Ref Ref 
Medicaid 0.86 0.51-1.46 0.588 
Medicare 0.89 0.56-1.40 0.612 
Self- Insured 1.00 0.12-8.10 0.998 
Missing 1 . . 
Region    
West Ref Ref Ref 
Midwest 1.72 0.82-3.62 0.154 
Northeast 1.33 0.70-2.52 0.391 
South 1.47 0.79-2.74 0.227 
Puerto Rico 0.67 0.25-1.84 0.441 
Missing 1 . . 
Numbers of Comorbidities    
With 1-4 comorbidities Ref Ref Ref 
With 5-7 comorbidities 1.27 0.85-1.90 0.240 




Table A.6 Characteristics Associated with Combination Pharmacotherapy (co-
morbidities)- With Cost 
 
 Odds Ratio 95% CI P value 
Cardiovascular disorders 0.87 0.49-1.54 0.623 
Diabetes-related condition 0.93 0.63-1.37 0.703 
Mental disorders 1.49 1.00-2.21 0.050 
Sleep disorders 0.91 0.51-1.61 0.738 












Table A.7 Characteristics Associated with Combination Pharmacotherapy (specific co-
morbidities)- With Cost 
 
 Odds Ratio 95% CI P value 
Cardiovascular disorders       
Congestive heart failure 1.28 0.77-2.14 0.345 
Peripheral vascular 
disease 
0.96 0.63-1.46 0.845 
Cerebrovascular disease 0.60 0.33-1.09 0.093 
Coronary heart disease 0.73 0.47-1.14 0.168 
Hypertension 1.08 0.71-1.65 0.704 
Hyperlipidemia 1.01 0.70-1.46 0.954 
Diabetes-related 
condition 
      
Retinopathy 0.87 0.50-1.51 0.618 
Nephropathy 1.01 0.64-1.61 0.960 
Mental disorders       
Depression 1.25 0.79-1.98 0.332 
Bipolar disorder 1.04 0.24-4.54 0.960 
Anxiety 1.58 0.83-3.04 0.166 
Sleep disorders       
Insomnia/sleep disorders 0.85 0.47-1.52 0.582 
Musculoskeletal pain 
conditions 
      
Arthritis and other 
arthropathies 
1.31 0.91-1.89 0.147 
Rheumatoid arthritis 0.51 0.12-2.12 0.354 
Low back pain 1.35 0.92-1.98 0.121 
Back and neck pain, 
other than low back pain 
1.44 0.90-2.30 0.126 
Rheumatism, excluding 
the back 
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